<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001070" GROUP_ID="NEONATAL" ID="382999091516021756" MERGED_FROM="" MODIFIED="2009-02-18 18:24:37 +0100" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Short title (no longer in use): Thyroid hormones in preterm infants&lt;/p&gt;&lt;p&gt;sent for update Oct/03&lt;br&gt;sent 12/04&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-02-18 12:21:38 -0500" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="2" REVMAN_SUB_VERSION="5.0.18" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2009-02-18 18:24:37 +0100" MODIFIED_BY="Diane Haughton">
<TITLE>Thyroid hormones for preventing neurodevelopmental impairment in preterm infants</TITLE>
<CONTACT MODIFIED="2009-02-18 18:24:37 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="17768" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Osborn</LAST_NAME><POSITION>Clinical Associate Professor</POSITION><EMAIL_1>david.osborn@email.cs.nsw.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>RPA Newborn Care</DEPARTMENT><ORGANISATION>Royal Prince Alfred Hospital</ORGANISATION><ADDRESS_1>Missenden Road</ADDRESS_1><CITY>Camperdown</CITY><ZIP>2050</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 95158363 </PHONE_1><FAX_1>+61 2 95504375 </FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-02-18 18:24:37 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="17768" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Osborn</LAST_NAME><POSITION>Clinical Associate Professor</POSITION><EMAIL_1>david.osborn@email.cs.nsw.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>RPA Newborn Care</DEPARTMENT><ORGANISATION>Royal Prince Alfred Hospital</ORGANISATION><ADDRESS_1>Missenden Road</ADDRESS_1><CITY>Camperdown</CITY><ZIP>2050</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 95158363 </PHONE_1><FAX_1>+61 2 95504375 </FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-02-18 12:21:38 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 11/15/06&lt;/p&gt;&lt;p&gt;Reformatted: 9/15/99&lt;/p&gt;" NOTES_MODIFIED="2009-02-18 12:21:38 -0500" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="2" MONTH="2" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="6" YEAR="2001"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2009-02-02 11:37:08 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-02 11:37:08 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>When preparing the update of the review "Thyroid hormones for preventing neurodevelopmental impairment in preterm<BR/>infants" in 2007, an editorial decision was made to split this review into three separate reviews noted below. The titles of these three reviews are listed below and should be referred to for the most current information.<BR/>
<BR/>1. Postnatal thyroid hormones for preterm infants with transient hypothyroxinaemia - Osborn DA, Hunt RW<BR/>2. Postnatal thyroid hormones for respiratory distress syndrome in preterm infants - Osborn DA, Hunt RW<BR/>3. Prophylactic postnatal thyroid hormones for prevention of morbidity and mortality in preterm infants - Osborn DA,<BR/>Hunt RW</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-02-02 11:35:27 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-02 11:33:28 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="12" MONTH="6" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-11 14:16:52 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-09-11 14:16:52 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-11 14:16:48 -0400" MODIFIED_BY="[Empty name]">Thyroid hormones for preventing neurodevelopmental impairment in preterm infants</TITLE>
<SUMMARY_BODY MODIFIED="2008-09-11 14:16:52 -0400" MODIFIED_BY="[Empty name]">
<P>No evidence from trials that thyroid hormone therapy is effective in preventing problems such as respiratory distress syndrome in preterm babies. Thyroid hormones are needed for the normal growth and maturity of the central nervous system, as well as the heart and lungs. Children born without sufficient thyroid hormones can develop serious mental retardation. It is believed that low levels of thyroid hormones in the first few weeks of life (transient hypothyroxinemia) in preterm babies born before 34 weeks may cause this abnormal development. The review of trials found no evidence that using thyroid hormones in preterm babies is effective in reducing the risk of problems caused by insufficient thyroid hormones.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Observational studies have shown an association between transiently low thyroid hormone levels in preterm infants in the first weeks of life (transient hypothyroxinemia) and abnormal neurodevelopmental outcome. Thyroid hormone therapy might prevent this morbidity.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess whether thyroid hormone therapy in preterm infants without congenital hypothyroidism results in clinically important changes in neonatal and long term outcomes in terms of benefits and harms.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The standard search strategy of the Neonatal Review Group was used. This included searches of the Oxford Database of Perinatal Trials, Cochrane Controlled Trials Register, MEDLINE, previous reviews including cross references, abstracts, conferences, symposia proceedings, expert informants and journal handsearching in the English language.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All trials using random or quasi-random patient allocation, in which thyroid hormone therapy (either treatment or prophylaxis) was compared to control in premature infants.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Primary clinical outcomes included measures of neurodevelopmental outcome and mortality. Assessment of trial quality, data extraction and synthesis of data, using relative risk (RR) and weighted mean difference (WMD), were performed using standard methods of the Cochrane Collaboration and its Neonatal Review Group.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Nine studies were identified that compared thyroid hormone treatment to control. Four randomized (Chowdhry 1984, van Wassenaer 1997; Vanhole 1997; Smith 2000) and one quasi-randomized study (Amato 1989) met inclusion criteria. All studies enrolled preterm infants &lt; 32 weeks gestation, but used different timing, dose and duration of treatment with thyroid hormones. Four studies used thyroxine, whereas Amato 1989 used triiodothyronine. Only two studies with neurodevelopmental follow-up were of good methodology (van Wassenaer 1997, Vanhole 1997). All studies were of small size with the largest, van Wassenaer 1997, enrolling 200 infants.</P>
<P>Meta-analysis of five studies found no significant difference in mortality to discharge (typical RR 0.70, 95% CI 0.42, 1.17) in infants who received thyroid hormone treatment compared to controls. Meta-analysis of two studies (van Wassenaer 1997; Vanhole 1997) found no significant difference in the Bayley MDI or PDI performed at 7-12 months. van Wassenaer 1997 found no significant differences in the Bayley MDI and PDI at 24 months, incidence of cerebral palsy (RR 0.72, 95% CI 0.28, 1.84), death and cerebral palsy (RR 0.70, 95% CI 0.43, 1.14) or the RAKIT IQ score (WMD -2.10, 95% CI -7.91, 3.71) at 5.7 years of age. Fraction of inspired oxygen was lower in infants receiving triiodothyronine in one small quasi-randomized study, but not in infants receiving thyroxine in a randomized study. Duration of mechanical ventilation and incidence of chronic lung disease were not reduced in infants receiving early thyroid hormone therapy.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>This review does not support the use of thyroid hormones in preterm infants to reduce neonatal mortality, improve neurodevelopmental outcome or to reduce the severity of respiratory distress syndrome. An analyses of data from one study (van Wassenaer 1997) which showed benefits in infants 24-25 weeks gestation was not prespecified and should be treated with caution. </P>
<P>The small number of infants included in trials incorporated in this review limits the power of the meta-analysis to detect clinically important differences in neonatal outcomes.</P>
<P>Future trials are warranted and should be of sufficient size to detect clinically important differences in neurodevelopmental outcomes. They should consider enrolling those infants most likely to benefit from thyroid hormone treatment such as infants born at less than 27 weeks gestation.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>In preterm infants, values for serum thyroxine and free thyroxine in the first days of life vary directly with gestation (<LINK REF="REF-Rooman-1996" TYPE="REFERENCE">Rooman 1996</LINK>, <LINK REF="REF-Reuss-1997" TYPE="REFERENCE">Reuss 1997</LINK>). However, unlike term infants the concentrations of thyroxine and free thyroxine decrease to reach a nadir between day 10 and 14 of life that is more severe at lower gestations and birth weights (<LINK REF="REF-Frank-1996" TYPE="REFERENCE">Frank 1996</LINK>, <LINK REF="REF-Rooman-1996" TYPE="REFERENCE">Rooman 1996</LINK>). <LINK REF="REF-Reuss-1997" TYPE="REFERENCE">Reuss 1997</LINK> found the incidence of infants with severely depressed thyroxine values (below 4 micrograms/dL) ranged from 40% at 23 weeks gestation to 10.2% at 28 weeks gestation. Furthermore, the levels of thyroxine and free thyroxine found in premature infants are lower than those seen in the normal fetus at similar gestational ages (<LINK REF="REF-Ballabio-1989" TYPE="REFERENCE">Ballabio 1989</LINK>, <LINK REF="REF-Thorpe_x002d_Beetson-1991" TYPE="REFERENCE">Thorpe-Beetson 1991</LINK>, <LINK REF="REF-Radunovic-1991" TYPE="REFERENCE">Radunovic 1991</LINK>).</P>
<P>This period of low thyroid hormone levels in infants born prematurely has been termed transient hypothyroxinemia of prematurity. Suggestions as to the cause of these low thyroid hormone values include an immaturity of the hypothalamic-pituitary-thyroid axis in the extremely premature infant or a form of "nonthyroidal illness" (the "sick euthyroid syndrome") reflecting the infant's response to severe illness (monograph review by <LINK REF="REF-Paneth-1998" TYPE="REFERENCE">Paneth 1998</LINK>).</P>
<P>Transient hypothyroidism (low thyroxine, high thyrotropin concentration) also occurs in up to 5% of neonates admitted to neonatal intensive care (<LINK REF="REF-Rooman-1996" TYPE="REFERENCE">Rooman 1996</LINK>), 0.4% of infants with birth weights &lt; 1500g (<LINK REF="REF-Frank-1996" TYPE="REFERENCE">Frank 1996</LINK>) and 1.8% of infants born &lt; 29 weeks gestation (<LINK REF="REF-Reuss-1997" TYPE="REFERENCE">Reuss 1997</LINK>). There is evidence to suggest that this may be due to exposure to iodine-containing antiseptics used in neonatal care (<LINK REF="REF-Linder-1997" TYPE="REFERENCE">Linder 1997</LINK>).</P>
<P>Thyroid hormones are necessary for the normal growth and maturation of the central nervous system (monograph reviews by <LINK REF="REF-Porterfield-1993" TYPE="REFERENCE">Porterfield 1993</LINK> and <LINK REF="REF-Bernal-1995" TYPE="REFERENCE">Bernal 1995</LINK>). Congenital hypothyroidism is strongly associated with abnormal neurodevelopment. Neurological cretinism in its severest form is characterised by profound mental retardation, deafmutism, spastic diplegia and squint (<LINK REF="REF-Porterfield-1993" TYPE="REFERENCE">Porterfield 1993</LINK>). Even children who receive early thyroid hormone replacement therapy for congenital hypothyroidism have motor and cognitive deficits that persist to late childhood (<LINK REF="REF-Kooistra-1994" TYPE="REFERENCE">Kooistra 1994</LINK>).</P>
<P>Infants born prematurely also have a high incidence of motor and cognitive deficits that are worse at lower gestations (<LINK REF="REF-Lorenz-1998" TYPE="REFERENCE">Lorenz 1998</LINK>). The question is whether the transient decrease in serum concentration of free thyroxine that occurs in some preterm infants during the first weeks of life is harmful.</P>
<P>Three cohort studies (<LINK REF="REF-Lucas-1988" TYPE="REFERENCE">Lucas 1988</LINK> and 1996, Miejer 1992 and <LINK REF="REF-den-Ouden-1996" TYPE="REFERENCE">den Ouden 1996</LINK>, and <LINK REF="REF-Reuss-1996" TYPE="REFERENCE">Reuss 1996</LINK>) have documented an association between low thyroid hormone levels (triiodothyronine or thyroxine) in the first weeks of life and abnormal neurodevelopmental outcome. All three cohorts documented a measure of abnormal mental development in children who had low neonatal thyroid hormone levels. One study (<LINK REF="REF-Reuss-1996" TYPE="REFERENCE">Reuss 1996</LINK>) found a 4.4 fold increase in risk of disabling cerebral palsy at 2 years. Den Ouden 1996 in the same cohort found children who had low neonatal thyroxine levels to have an increased risk of school failure at 9 years. The associations in the cohorts persisted despite correction for potential confounders including gestation, measures of fetal growth (either birth weight or presence of growth restriction) and, in some studies, many factors relating to severity of illness in preterm infants and independent risk factors for abnormal neurodevelopmental outcome.</P>
<P>Whether transient hypothyroxinemia of prematurity is a causative factor for abnormal neurodevelopment is uncertain. Transient hypothyroxinemia of prematurity is strongly correlated with low gestation and is more frequent in infants with respiratory distress syndrome and in ventilated infants (<LINK REF="REF-Franklin-1986" TYPE="REFERENCE">Franklin 1986</LINK>). It may be that transient hypothyroxinemia of prematurity is secondary to low gestation and/or illness severity in preterm infants. It is possible that other factors which are responsible for the abnormal neurodevelopmental outcome in preterm infants have not been taken into account adequately in the cohort studies.</P>
<P>Thyroid hormones have also been demonstrated to have a synergistic effect in stimulating lung maturation and surfactant production in animal models (<LINK REF="REF-Liggins-1988" TYPE="REFERENCE">Liggins 1988</LINK>). Although antenatal TRH administered to mothers to stimulate fetal thyroid hormone production has been shown to have limited effect (Cochrane review: <LINK REF="REF-Crowther-1998" TYPE="REFERENCE">Crowther 1998</LINK>), it has been suggested that thyroid hormones administered shortly after birth may also reduce the severity of respiratory distress syndrome (<LINK REF="STD-Amato-1988" TYPE="STUDY">Amato 1988</LINK>). No evidence of an effect of thyroid hormones administered post-natally on the severity of respiratory distress syndrome in an animal model could be found in the literature.</P>
<P>This review examines the evidence from randomized and quasi-randomized controlled trials of thyroid hormone therapy in preterm infants. Thyroid hormones have effects not only on neurological development but also on the respiratory and cardiovascular systems, and somatic growth. Therefore, studies that examined either neonatal morbidity, mortality and/or long term neurodevelopment were included in this review.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess whether thyroid hormone therapy in preterm infants without congenital hypothyroidism results in clinically important changes in neonatal and long term outcomes in terms of both benefits and harms. To determine the evidence for the use of different thyroid hormone preparations, doses and timing of treatment by subgroup analysis of the trials.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Trials using random or quasi-random patient allocation to treatment or control.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Studies that enrolled and treated preterm infants in the neonatal period.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Thyroid hormone therapy (either treatment or prophylaxis) compared to control (placebo or no therapy). Thyroid hormone therapy could be either thyroxine, triiodothyronine or both.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Primary clinical outcome measures were mortality (either neonatal or prior to discharge) and neurodevelopmental status at follow up. Neurodevelopmental outcome was categorized as:<BR/>1. Abnormal mental developmental (a development or intelligence quotient &gt; 2 standard deviations below the mean of a standardized test),<BR/>2. Abnormal neurological outcome (infants with either abnormal mental development or definite cerebral palsy or hearing deficit requiring aids or visual acuity &lt; 6/60),<BR/>3. Motor deficits, and<BR/>4. Sensorineural impairments.</P>
<P>Secondary outcome measures included important neonatal morbidities and measures of potential adverse effects of thyroid hormone treatment:<BR/>1. Severity of respiratory disease (use of IPPV or CPAP, maximum ventilation requirements, use of rescue therapies, incidence of air leak, duration of mechanical ventilation),<BR/>2. Patent ductus arteriosus diagnosed clinically or by echocardiography,<BR/>3. Intraventricular hemorrhage diagnosed by ultrasound or postmortem<BR/>4. Periventricular leucomalacia diagnosed by ultrasound or postmortem,<BR/>5. Chronic lung disease defined as oxygen at 28 days post-natal age or 36 weeks post-menstrual age,<BR/>6. Necrotizing enterocolitis,<BR/>7. Retinopathy of prematurity, and<BR/>8. Growth.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>The standard search strategy of the Neonatal Review Group was used. This included searches of the Oxford Database of Perinatal Trials, Cochrane Controlled Trials Register, MEDLINE, PREMEDLINE, EMBASE, previous reviews including cross references, abstracts, conferences (SPR-PAS 1998-2001and PSANZ 1998-2001), expert informants (authors of published trials and neonatologists) and journal handsearching in the English language.</P>
<P>MEDLINE (1966 to May 2001) was searched using MeSH terms '(infant-newborn or infant-premature) and (thyroxine or triiodothyronine)' and text words using '(hypothyroxinemia or hypothyroxinaemia or thyroxine or triiodothyronine) and [MeSH terms] (infant-newborn or infant-premature)'. EMBASE (1980 to 2001 Week 22) and PREMEDLINE (June 2001) were searched using terms '(hypothyroxinemia or hypothyroxinaemia or thyroxine or triiodothyronine) and newborn. The Oxford Database of Perinatal Trials was searched using the term 'thyroid disease', and the Cochrane Controlled Trials Register (2001, Issue 2) was searched using 'thyroxine or triiodothyronine or hypothyroxinemia or hypothyroxinaemia'.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Assessment of trial quality, data extraction and synthesis of data, using relative risk (RR) and weighted mean difference (WMD), were performed using standard methods of the Cochrane Collaboration and its Neonatal Review Group. The study by <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> was the subject of several publications. Additional data was obtained from the authors of three studies (<LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> and <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>). Data were synthesized using relative risk (RR) and risk difference (RD). From 1/RD the number needed to treat (NNT) for benefits and the number needed to harm (NNH) for adverse effects was calculated. All results are given with the 95% confidence intervals unless otherwise stated. Attempts to contact authors of the <LINK REF="STD-THORN" TYPE="STUDY">THORN</LINK> study have been unsuccessful.</P>
<P>Trials were included in the review if there was &gt; 80% ascertainment of the outcome in survivors analyzed on an intention to treat basis.</P>
<P>Trials using thyroid hormone therapy in unselected preterm infants, infants with respiratory distress and infants with low thyroid hormone levels were included in the review. This allows the review to explore differences in treatment effect in infants with different levels of risk for abnormal outcomes.</P>
<P>Subgroup analysis was performed for those trials using good methodology as defined by the use of a random method of allocation to treatment or control, if steps were taken to ensure allocation concealment and if there was at least 90% follow up of survivors.</P>
<P>Subgroup analyses were performed according to thyroid hormone therapy used (triiodothyronine or thyroxine); timing of thyroid hormone therapy (early &lt; 24 hours age); dosage of thyroid hormone preparation used; use of thyroid hormones as prophylaxis (of all preterm infants irrespective of thyroid hormone status); and as treatment (of preterm infants with low thyroid hormone levels).</P>
<P>Subgroup analysis by gestational age at birth performed by one study (<LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>) suggesting a difference in effect at different gestations was not prespecified.</P>
<P>Only trials that commenced thyroid hormone treatment early (&lt; 24 hours) were included in the analyses of short term respiratory outcomes.</P>
<P>Where appropriate, data for some outcomes were pooled despite differences between studies in the method of ascertainment of the outcome (see description of studies for definitions used in individual studies). These outcomes included chronic lung disease (oxygen at 28 days), patent ductus arteriosus and intraventricular hemorrhage (any grade and grade 3 or 4).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Studies included in this review are: <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK>, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> and <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>. Details of each study are given in the table 'Characteristics of Included Studies' and references. No ongoing trials of thyroid hormone replacement are currently known. A trial of thyroid hormone treatment in preterm infants has been proposed and is in the design phase (<LINK REF="STD-Golombek" TYPE="STUDY">Golombek</LINK>).</P>
<P>Studies excluded from this review are: <LINK REF="STD-Schonberger-1981" TYPE="STUDY">Schonberger 1981</LINK> (used alternation and included non-alternated infants in control group), <LINK REF="STD-Eggermont-1984" TYPE="STUDY">Eggermont 1984</LINK> (non-randomized trial), <LINK REF="STD-Amato-1988" TYPE="STUDY">Amato 1988</LINK> (used alternation and excluded 25% of infants after alternation), and <LINK REF="STD-van-Wassenaer-1993" TYPE="STUDY">van Wassenaer 1993</LINK> (non-randomised study).</P>
<P>Studies awaiting assessment: <LINK REF="STD-THORN" TYPE="STUDY">THORN</LINK> trial (Thyroid hormone replacement in neonates). </P>
<P>Types of participants:<BR/>All studies enrolled very preterm infants but used different entry criteria. <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK> enrolled infants &lt; 1250g and 25-28 weeks' gestation who were demonstrated to have hypothyroxinemia (thyroxine &lt; 4 micrograms/dL and thyrotropin &lt; 20 IU/L) on two occasions. Thyroid function was not an entry criterion for any other study. <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> enrolled infants born &lt; 32 weeks' gestation in &gt; 40% oxygen with a clinical and x-ray diagnosis of respiratory distress syndrome. Van Wassenaer 1997 enrolled infants born 25-29 weeks' gestation. <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> enrolled infants born 25-30 weeks' gestation with available cord blood for baseline thyroid function. <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK> enrolled infants &lt; 32 weeks' gestation and 600-1500g. Three studies (<LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> and <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>) excluded infants with congenital malformations and maternal endocrine disease.</P>
<P>Interventions:<BR/>Three studies (<LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> and <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>) compared thyroxine treatment to placebo, whereas <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> compared triiodothyronine treatment to no treatment. <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK> treated infants with thyroxine 10 micrograms/kg/day given intramuscularly until tolerating feeds, then orally. <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> treated infants with L-triiodothyronine 50 micrograms/day in 2 divided doses for 2 days intravenously starting on the first day. Van Wassenaer 1997 treated infants with thyroxine 8 micrograms/kg birthweight (intravenously until tolerating feeds, then orally), from 12-24 hours of age, for 6 weeks. <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> treated infants with thyroxine 20 micrograms/kg/day intravenously for 2 weeks from the first day. <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK> treated infants, starting before 48 hours age, with thyroxine 10 micrograms/kg/day intravenously till tolerating feeds, then 20 micrograms/kg/day for a total 21 days.</P>
<P>Outcomes:<BR/>A principal outcome was stated by two studies, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> (Bayley MDI at 24 months) and <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK> (oxygen at 28 days). Other studies stated broader objectives: <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> assessed the effect of thyroxine on the course and severity of respiratory distress syndrome. <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK> assessed the effect of thyroid hormone therapy on growth and development. <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> assessed its impact on a variety of endocrine and clinical outcomes.</P>
<P>Mortality was assessed by all the included studies with data for neonatal mortality available for <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> and <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>, and mortality to time of discharge for all studies. <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> did not document time of death of four infants (all died from intraventricular hemorrhage). These infants were included in deaths to discharge.</P>
<P>Neurodevelopment was assessed by <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> and <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK>. The Bayley MDI and the Bayley Psychomotor Development Index (PDI) were used by <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> at 12 and 24 months corrected age and <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> at 7 months corrected age. <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> assessed neurological outcome at 6 and 12 months (method of Touwen) and 24 months (method of Hempel). At mean age 5.7 years, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> assessed cognitive (RAKIT IQ score), behaviour, motor and neurologic (method of Touwen) outcome. As only 38% of survivors received neurodevelopmental assessment in the study by <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, this study is excluded from any analysis of neurodevelopmental outcome.</P>
<P>Data for chronic lung disease defined as oxygen requirements at 28 days were obtained from the studies by <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK>, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> and <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>. <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> defined chronic lung disease as oxygen requirements at 28 days with an abnormal chest x-ray. These data are pooled. Data were available from <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> and <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> for infants with chronic lung disease as defined by oxygen requirements at 36 weeks post-menstrual age.</P>
<P>Patent ductus was diagnosed clinically by <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> and clinically with ultrasound confirmation by <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>. Intraventricular hemorrhage was detected by ultrasound by <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK>, and ultrasound and post-mortem by <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>. Data were obtained from the author for intraventricular hemorrhage and patent ductus arteriosus from the study by <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> and for patent ductus arteriosus from the study by <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, although no definitions were given.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Randomization: four studies used a random method of allocation to treatment. <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK> randomized infants in pharmacy by "drawing cards". <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> used computerised block randomization. <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> used randomized envelopes. <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK> used sequentially numbered envelopes stratified by center. <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> was a "quasi-random" study, treating alternate patients. </P>
<P>There were no significant differences between treatment and control groups after randomization in terms of birth weights, gestational ages, Apgar scores or the male/female ratio in any of the studies. <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> had fewer infants &lt; 27 weeks gestation (19 versus 27) and more very small for gestational age infants (5 versus 2) in the treatment group compared to the control group. In the neurodevelopmental follow up of 25-26 weeks' gestation survivors, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> found a significant lower mean birth weight in the treatment group (n = 13) compared to the placebo group (n = 18) (856 +/- 153g versus 914 +/- 111g; p = 0.04). <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK> had fewer infants randomised to control (20) than to treatment (29). No reason was given (reply from the author awaited).</P>
<P>Blinding of treatment: <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> and <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK> used placebo treatment in the control arm. <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> was unblinded by the use of alternation and no treatment in the control arm.</P>
<P>Blinding of outcome assessment: <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> and <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK> performed blinded assessment of clinical and neurodevelopmental outcomes. <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> did not state whether the assessment of clinical outcomes was blinded.</P>
<P>Exclusions after randomization: <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK> followed all infants up for short term clinical outcomes but assessed only 38% of survivors for neurodevelopmental. <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> excluded 6 (12%) infants (3 treatment and 3 controls) after alternation as they had respiratory diagnoses other than respiratory distress syndrome. Van Wassenaer 1997 had 7 (4%) losses to neurodevelopmental follow up at 24 months corrected age (4 treatment and 3 controls) due to withdrawals from trial or the diagnosis of a congenital anomaly, and 9 (5 treatment and 4 controls) at 5.7 years. <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> excluded 6 (15%) neonatal deaths from analysis of neonatal morbidities, but assessed neurodevelopment of all survivors at 7 months corrected age. <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK> excluded 2 infants (4%) from the control group.</P>
<P>Studies with good methodology: four studies (<LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>) were of good methodology with adequate randomization, allocation concealment and &gt; 90% follow up of survivors. <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> was excluded due to use of non-random allocation to treatment (alternation) and 12% post alternation exclusions, and <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK> was excluded from analysis of neurodevelopmental outcomes due to inadequate follow up. <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> and <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK> were included for all available outcomes.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>See "tables of analyses".</P>
<P>Neurodevelopment:<BR/>No significant difference was found in any measure of neurodevelopmental outcome in infants who received neonatal thyroid hormone replacement compared to controls. There was no significant difference in the mortality rate or combined mortality and abnormal neurological outcome in infants who received thyroid hormone treatment compared to controls.</P>
<P>Neurodevelopment: <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> found no difference in the risk of abnormal mental development (&gt; 2sd below mean) at 6, 12, 24 months or 5.7 years (at 5.7 years relative risk 0.66, 95% CI 0.22, 1.99) in infants receiving thyroid hormones compared to controls. There was no significant difference in the risk of cerebral palsy assessed at 5.7 years (RR 0.72, 95% CI 0.28, 1.84). Meta-analysis of two studies, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> and <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK>, found no difference in the Bayley MDI (weighted mean difference -1.14, 95% CI -5.46, 3.19) and PDI (WMD 0.22 points, 95% CI -4.80, 5.24) at 7-12 months. <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> found no difference in the Bayley MDI (MD -3.50 points, 95% CI -11.21, 4.21) and PDI (MD 3.10 points, 95% CI -3.31, 9.51) at 24 months. <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> found similar RAKIT IQ scores at 5.7 years (MD -2.10 points, 95% CI -7.91, 3.71). At 2 years the risk of a clinically significant Child Behavioural Checklist (CBCL) score (RR 0.81, 95% CI 0.35, 1.86) was not significantly different. At 5.7 years, the risk of a clinically significant CBCL score (RR 1.17, 95% CI 0.57, 2.40) and Teacher Report Form (TRF) score (RR 1.08, 95% CI 0.55, 2.10) were not significantly different.</P>
<P>In post hoc subgroup analyses, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> found a significant reduction in the incidence of abnormal mental development at 24 months in infants born 25-26 weeks gestation (RR 0.10, 95% CI 0.01, 0.70). However, there was no significant difference in abnormal mental development in infants born 27-29 weeks' gestation (RR 1.32, 95% CI 0.46, 3.82). There was a significant increase in the Bayley MDI at 24 months in treated infants of 25-26 weeks' gestation (MD 18.0 points, 95% CI 0.3 to 35.7), but a significant decrease in the Bayley MDI at 24 months in treated infants of 27-29 weeks' gestation (MD -10.0 points, 95% CI -18.4 to -1.6). At 5.7 years, the difference in the RAKIT IQ score was no longer significant in infants 25-26 weeks (MD 9.50 points, 95% CI -0.88, 19.88) but was significant in infants 29 weeks' gestation (MD -14.6 points, 95% CI -25.14, -4.06). There were no differences at any gestation in the psychomotor scores or incidences of cerebral palsy. Infants 25-27 weeks had an increased incidence of clinically significant CBCL problem scores.</P>
<P>Death:<BR/>Meta-analysis of all five trials does not support a decreased incidence of mortality to discharge in infants receiving thyroid hormone treatment (typical RR 0.70, 95% CI 0.42 to 1.17).</P>
<P>Death or cerebral palsy: data were available from one study, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> with no significant difference at 5.7 years (RR 0.70, 95% CI 0.43 to 1.14).</P>
<P>Neonatal morbidity:<BR/>Severity of respiratory disease:<BR/>Ventilation and oxygen requirements: no data could be pooled for meta-analysis. No data were obtained for short term outcomes such as maximal oxygenation index or use of rescue therapies. <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> found a significant reduction at 12 to 72 hours in the fraction of inspired oxygen, but not peak inspiratory pressure, mean airway pressure or oxygenation, in the triiodothyronine treated infants. <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> found no difference in the inspired oxygen requirements in the first 6 days of life.</P>
<P>Airleak: one study, <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK>, found no difference in pulmonary airleak in infants with respiratory distress syndrome treated with thyroid hormones (RR 0.75, 95% CI 0.19 to 2.97).</P>
<P>Duration of mechanical ventilation: meta-analysis of three trials (<LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>) found no significant difference in duration of mechanical ventilation (WMD -2.44 days, 95% CI -5.41 to 0.53). <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK> reported no difference in the duration of ventilation (no data given).</P>
<P>Chronic lung disease: meta-analysis of all five trials found no significant difference in incidence of chronic lung disease at 28 days postnatal age (typical RR 0.96, 95% CI 0.75, 1.23). Meta-analysis of three trials (<LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK>) reported no significant difference in incidence of oxygen requirements at 36 weeks postmenstrual age (typical RR 1.02, 95% CI 0.64, 1.64).</P>
<P>Patent ductus arteriosus: meta-analysis of five trials found no significant difference in incidence of clinically or echocardiographically diagnosed patent ductus arteriosus (typical RR 0.76, 95% CI 0.56, 1.03).</P>
<P>Intraventricular haemorrhage: meta-analysis of three trials (<LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK>, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK>) does not support any benefit of thyroid hormone treatment on the incidence of intraventricular hemorrhage (typical RR 1.20, 95% CI 0.88, 1.63). Meta-analysis of three trials (<LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>) found no difference in incidence of severe (grade 3 or 4) intraventricular hemorrhage (typical RR 1.07, 95% CI 0.55, 2.11).</P>
<P>Periventricular leucomalacia: meta-analysis of two trials (<LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>) found no significant difference in incidence of periventricular leucomalacia (typical RR 0.84, 95% CI 0.16, 4.38).</P>
<P>Necrotizing enterocolitis: meta-analysis of two trials (<LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK>) found no significant difference in incidence of necrotizing enterocolitis (typical RR 0.35, 95% CI 0.04, 3.16).</P>
<P>Retinopathy of prematurity: meta-analysis of three trials (<LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK>, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>) found no significant difference in incidence of retinopathy of prematurity (typical RR 0.93, 95% CI 0.49, 1.78). <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> reported only cicatricial 'retrolental fibroplasia' (RR 0.50, 95% CI 0.05, 5.08).</P>
<P>Growth: one study reported data on rates of growth (<LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>). There was no significant difference in the rates of weight increase (MD 0.5 grams/day, 95% CI -2.5, 3.6), rates of growth in head circumference (MD 0.02 cm/week, 95% CI -0.15, 0.19), or growth in length (MD -0.06 cm/week, 95% CI -0.24, 0.12). <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> also found no difference in growth rates of infants receiving thyroxine treatment (displayed as graph in paper).</P>
<P>Other outcomes: in a subgroup of infants, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> found no effect of thyroxine therapy on somatosensory evoked potentials at 2 weeks, term and 6 months of age (reference d). At the same intervals, motor nerve conduction velocity was also not significantly affected in 80 treated infants compared to 83 controls (reference e). <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> found no effect of thyroxine treatment on heart rate, percentage of enteral fluid intake, or on weight gain. One study (<LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>) reported an reduction in sepsis in infants receiving thyroxine (RR 0.51, 95% CI 0.26, 0.98) which was reported in the article as not significant using the chi-square test at the p = 0.05 level.</P>
<P>Studies with good methodology: the four studies of good methodology (<LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>) all used thyroxine in the treatment group. <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK> was excluded from analysis of neurodevelopmental outcomes. The results of this review are not changed by incorporating only studies with good methodology. The neurodevelopmental outcomes are the same, and meta-analysis of the four studies shows no difference in neonatal mortality. All other neonatal outcomes are similar.</P>
<P>Thyroid hormone preparation used: four studies (<LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>) used thyroxine. The studies and results are the same as those described above in "studies with good methodology". Only <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> used triiodothyronine (for 2 days) to determine the effect of therapy on the severity of respiratory distress syndrome. Neurodevelopment was not assessed. No significant difference in mortality was found (RR 1.00, 95% CI 0.15 to 6.48). Apart from a reduced fraction of inspired oxygen in the first 72 hours, no significant differences were found in the incidences of any other neonatal outcome including air leak, duration of mechanical ventilation, oxygen at 28 days, patent ductus arteriosus, intraventricular hemorrhage, necrotizing enterocolitis or cicatricial 'retrolental fibroplasia'.</P>
<P>
<LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK> was the only study to use thyroid hormones as treatment for infants with transiently low thyroid hormone levels (transient neonatal hypothyroxinemia). Neurodevelopmental follow-up was inadequate. No significant difference in mortality to discharge was found (RR 1.09, 95% CI 0.08, 15.42).</P>
<P>Thyroid hormones were used as prophylaxis (in unselected preterm infants without documented low thyroid hormone levels) by four studies (<LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK>, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>). Three of these studies (<LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK>; <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK>; <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>) commenced treatment within 24 hours of birth, with <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK> commencing treatment before 48 hours. <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> was the only study to find a difference in a short term measure of respiratory function with a lower inspired oxygen in the treatment group in the first 72 hours. No other differences were found in any other respiratory outcome in any of the studies including incidence of airleak, duration of mechanical ventilation or incidence of chronic lung disease (at 28 days or 36 weeks).</P>
<P>Various doses of thyroxine were used in three trials with <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK> using 10 micrograms/kg/day from day 15 of life for 7 weeks, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> using 8 micrograms/day from day one of life for 6 weeks, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> using 20 micrograms/kg/day from day 1 for 2 weeks and <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK> 10 micrograms/kg/day IV then 20 micrograms/kg/day orally for total 21 days. Neurodevelopmental outcomes are only available for <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> and <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> who both used thyroxine from day one. Van Wassenaer 1997 found no significant difference in incidence of cerebral palsy or mental development at 5.7 years. <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> found a nonsignificant reduction in the Bayley MDI at 7 months corrected age. In a post hoc subgroup analysis, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> found a difference in effect according to gestation, with infants born at 25-26 weeks gestation having significantly higher mean mental scores in the treatment group, but infants born at 27-29 weeks gestation having significantly lower scores in the treatment group. The differences in the cognitive scores for infants 25-26 weeks were no longer significant at 5.7 years but were for infants at 29 weeks. No other differences were found for other outcomes including mortality, respiratory distress syndrome, and chronic lung disease. </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Nine studies were identified that compared thyroid hormone treatment to placebo or no treatment. Four studies were excluded: <LINK REF="STD-Schonberger-1981" TYPE="STUDY">Schonberger 1981</LINK> (used alternation and included non-alternated infants in control group), <LINK REF="STD-Eggermont-1984" TYPE="STUDY">Eggermont 1984</LINK> (non-randomized trial), <LINK REF="STD-Amato-1988" TYPE="STUDY">Amato 1988</LINK> (used alternation and excluded 25% of infants after alternation), and <LINK REF="STD-van-Wassenaer-1993" TYPE="STUDY">van Wassenaer 1993</LINK> (non-randomised study).</P>
<P>Five studies were included in this review (<LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>, <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK>, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>). All studies enrolled preterm infants but used different entry criteria. <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> studied infants &lt; 32 weeks' gestation with respiratory distress syndrome. <LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK> studied infants 25-28 weeks gestation and &lt; 1250 grams with low thyroxine levels (T4 &lt; 4 microgram/dl) on two occasions. <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> studied infants 25-29 weeks gestation, <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> infants 25-30 weeks gestation with cord blood available and <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK> infants &lt; 32 weeks.</P>
<P>Limitations to this review:<BR/>Major limitations of this review include: the small number of infants enrolled in trials incorporated in the review resulting in limited power of this review to detect moderate but clinically important differences in effect of thyroid hormone therapy in preterm infants; and the fact that studies used different treatments, doses and enrolment criteria limiting the ability to make conclusions from pooled results. This review examines the clinical effect of thyroid hormone therapy and does not address the question of what levels of thyroid hormones should be targeted in preterm infants, and what types and doses of thyroid hormones should be used to achieve these levels.</P>
<P>For primary outcomes, limited comparable data were available for meta-analytic pooling of results for neurodevelopment, but data were complete for all studies with respect to mortality to discharge.</P>
<P>Limitations of studies:<BR/>Two studies (<LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> and <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK>) with adequate neurodevelopmental follow up were of good methodology, whereas one study (<LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>) with good methodology for short term outcomes had inadequate neurodevelopmental follow up. <LINK REF="STD-Amato-1989" TYPE="STUDY">Amato 1989</LINK> used alternation and had &gt; 10% exclusions after alternation. The largest study with 200 infants, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, had non-significant differences in neonatal risk factors in the two groups after randomization, with fewer infants &lt; 27 weeks and more infants &lt; 3rd percentile for weight in the treatment group. <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK> had more infants randomised to the treatment group (29 versus 20). </P>
<P>Four studies used thyroid hormones prophylactically in infants at risk of transient hypothyroxinemia, whereas only one study (<LINK REF="STD-Chowdhry-1984" TYPE="STUDY">Chowdhry 1984</LINK>) treated only infants with demonstrated hypothyroxinemia. This study did not achieve adequate neurodevelopmental follow up. No study with adequate neurodevelopmental follow up treated infants with demonstrated hypothyroxinemia or was restricted to those most likely to benefit (infants &lt;27 weeks' gestation).</P>
<P>The studies were small (four enrolling between 23 and 49 infants), with <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> the largest enrolling a total of 200 infants. The small numbers of patients studied limits the power of this review to detect a moderate, but potentially important change in neurodevelopmental outcome.</P>
<P>The review does not support any beneficial effect of thyroid hormone treatment in preterm infants on subsequent neurodevelopment. <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> found no difference in the risk of cerebral palsy or abnormal mental development at 6, 12, 24 months or 5.7 years. Both <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> and <LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK> found no significant differences in developmental or intelligence quotients in treated infants compared with controls.</P>
<P>In post hoc subgroup analysis, <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> found that there was a significant increase in the Bayley MDI at 24 months in treated infants of 25-26 weeks gestation, but a significant decrease in the Bayley MDI at 24 months in treated infants of 27-29 weeks' gestation. This finding in infants of 24-25 weeks' gestation should be treated with caution as the analysis was not prespecified, there were imbalances in risk factors between the groups after randomization, the difference in IQ scores for infants 25-26 weeks gestation was no longer significant at 5.7 years and the overall finding of no effect for the combined gestations. This does not preclude a benefit of thyroid hormone therapy in preterm infants &lt; 27 weeks' gestation.</P>
<P>Meta-analysis of all five trials does not support a decrease in mortality in infants receiving thyroid hormone treatment. The trend to a reduction in combined mortality and cerebral palsy in one study (<LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>) does not reach significance. If the effect on combined mortality and cerebral palsy is of a magnitude found by <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK> (RR 0.70, 95% CI 0.43, 1.14), then this would be a clinically important effect.</P>
<P>For secondary outcomes, no significant differences were found for any neonatal morbidity including chronic lung disease, patent ductus arteriosus, intraventricular hemorrhage, retinopathy of prematurity and growth. Fraction of inspired oxygen was lower in infants receiving triiodothyronine in one small quasi-randomized study, but not in infants receiving thyroxine in a randomized study (<LINK REF="STD-Vanhole-1997" TYPE="STUDY">Vanhole 1997</LINK>). The reduction in sepsis (<LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>) was reported as non-significant by the authors. No other study reported this outcome. No other significant differences were found to suggest a reduced severity of respiratory distress syndrome including incidence of airleak, duration of mechanical ventilation or incidence of chronic lung disease.</P>
<P>There is no apparent heterogeneity in the findings of the different studies. The conclusions are not altered by excluding studies with inadequate methodology. The review finds no evidence of benefit from any individual thyroid hormone preparation, dose, timing or duration of treatment used by the included studies.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>This review does not support the use of thyroid hormones in preterm infants to reduce neonatal mortality, improve neurodevelopmental outcome or reduce the severity of respiratory distress syndrome. The post hoc analyses of data from one study (<LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>) which showed benefits in infants 24-25 weeks' gestation should be treated with caution. There is no evidence of benefit from treatment of transient hypothyroxinemia in preterm infants.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The small number of infants included in trials incorporated in this review limits the power of the meta-analysis to detect clinically important differences in neonatal outcomes. The findings of this review do not preclude a benefit of thyroid hormone treatment in extremely preterm infants or infants with hypothyroxinemia. </P>
<P>Future trials should be of sufficient size to detect clinically important differences in neurodevelopmental outcomes. To detect the magnitude of effect on the incidence of abnormal neurological outcome as found in the study by <LINK REF="STD-van-Wassenaer-1997" TYPE="STUDY">van Wassenaer 1997</LINK>, a trial would need to enrol 1670 infants. This number would provide 80% power to detect a 40% reduction in death or cerebral palsy (from 12 to 7%) at the 95% confidence level (assuming a 25% mortality rate).</P>
<P>Future trials should consider enrolling only those infants most likely to benefit from thyroid hormone treatment. This may include enrolling only infants &lt; 27 weeks' gestation. Trials should incorporate neurodevelopmental follow up most likely to detect abnormalities resulting from low thyroid hormone levels in preterm infants. This includes the use of standardized tests of mental and psychomotor development, examination for cerebral palsy, as well as follow up to school age to detect cognitive deficits and evidence of school failure.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Dr Parveen Chowdhry, Professor F de Zegher, Dr Aleid van Wassenaer and Dr Christine Vanhole for kindly responding to the request for additional information. Professor David Henderson-Smart assisted with methodological issues with this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>When preparing the update of the review "Thyroid hormones for preventing neurodevelopmental impairment in preterm infants", an editorial decision was made to split this review into three separate reviews noted below . These reviews are now published in Issue 1, 2007 and should be referred to for the most current information. </P>
<P>1. Postnatal thyroid hormones for preterm infants with transient hypothyroxinaemia - Osborn DA, Hunt RW <BR/>2. Postnatal thyroid hormones for respiratory distress syndrome in preterm infants - Osborn DA, Hunt RW <BR/>3. Prophylactic postnatal thyroid hormones for prevention of morbidity and mortality in preterm infants - Osborn DA, Hunt RW</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-11 14:23:00 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-09-11 14:23:00 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-09-11 14:23:00 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Amato-1989" NAME="Amato 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amato M, Guggisberg C, Schneider H</AU>
<TI>Postnatal triiodothyronine replacement and respiratory distress syndrome of the preterm infant</TI>
<SO>Horm Res</SO>
<YR>1989</YR>
<VL>32</VL>
<PG>213-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Chowdhry-1984" NAME="Chowdhry 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chowdhry P, Scanlon JW, Auerbach R, Abbassi V</AU>
<TI>Results of controlled double-blind study of thyroid replacement in very low-birth-weight premature infants with hypothyroxinemia</TI>
<SO>Pediatrics</SO>
<YR>1984</YR>
<VL>73</VL>
<PG>301-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2000" NAME="Smith 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith LM, Leake RD, Berman N, Villanueva S, Brasel JA</AU>
<TI>Postnatal thyroxine supplementation in infants less than 32 weeks' gestation: effects on pulmonary morbidity</TI>
<SO>J Perinatol</SO>
<YR>2000</YR>
<VL>20</VL>
<PG>427-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-van-Wassenaer-1997" MODIFIED="2008-09-11 14:23:00 -0400" MODIFIED_BY="[Empty name]" NAME="van Wassenaer 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Briet JM, van Wassenaer AG, Dekker FW, de Vijlder JJ, van Baar A, Kok JH</AU>
<TI>Neonatal thyroxine supplementation in very preterm children: developmental outcome evaluated at early school age</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>107</VL>
<PG>712-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Briet JM, van Wassenaer AG, van Baar A, Dekker FW, Kok JH</AU>
<TI>Evaluation of the effect of thyroxine supplementation on behavioural outcome in very preterm infants</TI>
<SO>Dev Med Child Neurol</SO>
<YR>1999</YR>
<VL>41</VL>
<PG>87-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smit BJ, Kok JH, de Vries LS, van Wassenaer AG, Dekker FW, Ongerboer de Visser BW</AU>
<TI>Somatosensory evoked potentials in very preterm infants in relation to L-thyroxine supplementation</TI>
<SO>Pediatrics</SO>
<YR>1998</YR>
<VL>101</VL>
<PG>865-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smit BJ, Kok JH, de Vries LS, van Wassenaer AG, Dekker FW,Ongerboer de Visser BW</AU>
<TI>Motor nerve conduction velocity in very preterm infants in relation to L-thyroxine supplementation</TI>
<SO>J Pediatr</SO>
<YR>1998</YR>
<VL>132</VL>
<PG>64-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-11 14:23:00 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Wassenaer AG, Kok JH, Briet JM, Pijning AM, de Vijlder JJ</AU>
<TI>Thyroid function in very preterm newborns: possible implications</TI>
<SO>Thyroid</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>85-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Wassenaer AG, Kok JH, Briet JM, van Baar A, de Vijlder JJ</AU>
<TI>Thyroid function in preterm newborns; is T4 treatment required in infants &lt;27 weeks' gestational age?</TI>
<SO>Exp Clin Endocrinol Diabetes</SO>
<YR>1997</YR>
<VL>105</VL>
<NO>S4</NO>
<PG>12-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Wassenaer AG, Kok JH, Dekker FW, Endert E, de Vijlder JJ</AU>
<TI>Thyroxine administration to infants of less than 30 weeks gestational age decreases plasma tri-iodothyronine concentrations</TI>
<SO>Eur J Endocrinol</SO>
<YR>1998</YR>
<VL>139</VL>
<PG>508-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Wassenaer AG, Kok JH, de Vijlder JJ, Briet JM, Smit BJ, Tamminga P, van Baar A, Dekker FW, Vulsma T</AU>
<TI>Effects of thyroxine supplementation on neurologic development in infants born at less than 30 weeks' gestation</TI>
<SO>N Engl J Med</SO>
<YR>1997</YR>
<VL>336</VL>
<PG>21-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Wassenaer, Kok JH, Dekker FW, de Vijlder JJ</AU>
<TI>Thyroid function in very preterm infants: influences of gestational age and disease</TI>
<SO>Pediatr Res</SO>
<YR>1997</YR>
<VL>42</VL>
<PG>604-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Vanhole-1997" NAME="Vanhole 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanhole C, Aerssens P, Devlieger H, de Zegher F</AU>
<TI>L-Thyroxine treatment of preterm newborns</TI>
<SO>Pediatr Res</SO>
<YR>1996</YR>
<VL>40</VL>
<PG>555</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vanhole C, Aerssens P, Naulaers G, Casneuf A, Devlieger H, Van den Berghe G, de Zegher F</AU>
<TI>L-thyroxine treatment of preterm newborns: clinical and endocrine effects</TI>
<SO>Pediatr Res</SO>
<YR>1997</YR>
<VL>42</VL>
<PG>87-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Amato-1988" NAME="Amato 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amato M, Pasquier S, Carasso A, Von Muralt G</AU>
<TI>Postnatal thyroxine administration for idiopathic respiratory distress syndrome in preterm infants</TI>
<SO>Horm Res</SO>
<YR>1988</YR>
<VL>29</VL>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eggermont-1984" NAME="Eggermont 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eggermont E, Vanderschueren Lodeweyckx M, De Nayer P, Smeets E, Vanacker G, Cornette C, Jaeken J, Devlieger H, Eeckels R, Beckers C</AU>
<TI>The thyroid-system function in preterm infants of postmenstrual ages of 31 weeks or less: evidence for a "transient lazy thyroid system"</TI>
<SO>Helv Paediatr Acta</SO>
<YR>1984</YR>
<VL>39</VL>
<PG>209-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schonberger-1981" NAME="Schonberger 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schonberger W, Grimm W, Emmrich P, Gempp W</AU>
<TI>Reduction of mortality rate in premature infants by substitution of thyroid hormones</TI>
<SO>Eur J Pediatr</SO>
<YR>1981</YR>
<VL>135</VL>
<PG>245-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Wassenaer-1993" NAME="van Wassenaer 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Wassenaer AG, Kok JH, Endert E, Vulsma T, de Vijlder JJ</AU>
<TI>Thyroxine administration to infants of less than 30 weeks' gestational age does not increase plasma triiodothyronine concentrations</TI>
<SO>Acta Endocrinol Copenh</SO>
<YR>1993</YR>
<VL>129</VL>
<PG>139-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-THORN" NAME="THORN" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Markiewicz M. THORN (Thyroid hormone replacement in neonates). British Association of Perinatal Medicine Clinical Trials Group Newsletter No. 12, Summer 1998.&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Markiewicz M</AU>
<TI>THORN (Thyroid hormone replacement in neonates)</TI>
<SO>British Association of Perinatal Medicine Clinical Trials Group Newsletter.</SO>
<YR>Summer 1998</YR>
<VL>No. 12</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Golombek" NAME="Golombek" YEAR="2001">
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-09-11 14:22:02 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-09-11 14:20:54 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Amato-1988" NAME="Amato 1988" TYPE="JOURNAL_ARTICLE">
<AU>Amato M, Pasquier S, Carasso A, Von Muralt GSO</AU>
<TI>Postnatal thyroxine administration for idiopathic respiratory distress syndrome in preterm infants</TI>
<SO>Horm-Res</SO>
<YR>1988</YR>
<VL>29</VL>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ballabio-1989" NAME="Ballabio 1989" TYPE="JOURNAL_ARTICLE">
<AU>Ballabio M, Nicolini U, Jowett T, Ruiz de Elvira MC, Ekins RP, Rodeck CH</AU>
<TI>Maturation of thyroid function in normal human foetuses</TI>
<SO>Clin Endocrinol</SO>
<YR>1989</YR>
<VL>31</VL>
<PG>565-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bernal-1995" NAME="Bernal 1995" TYPE="JOURNAL_ARTICLE">
<AU>Beranl J, Nunez J</AU>
<TI>Thyroid hormones and brain development</TI>
<SO>Eur J Endocrinol</SO>
<YR>1995</YR>
<VL>133</VL>
<PG>390-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crowther-1998" MODIFIED="2008-09-11 14:20:54 -0400" MODIFIED_BY="[Empty name]" NAME="Crowther 1998" TYPE="COCHRANE_REVIEW">
<AU>Crowther CA, Alfirevic Z, Haslam RR</AU>
<TI>Prenatal thyrotropin-releasing hormone for preterm birth</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-09-11 14:20:54 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-11 14:20:54 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000019"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-den-Ouden-1996" NAME="den Ouden 1996" TYPE="JOURNAL_ARTICLE">
<AU>den Ouden AL</AU>
<TI>Kok JH, Verkerk PH, Brand R, Verloove-Vanhorick SP. The relation between neonatal thyroxine levels and neurodevelopmental outcome at age 5 and 9 years in a national cohort of very preterm and/or very low birth weight infants</TI>
<SO>Pediatr Res</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>142-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frank-1996" NAME="Frank 1996" TYPE="JOURNAL_ARTICLE">
<AU>Frank JE, Faix JE, Hermos RJ, Mullaney DM, Rojan DA, Mitchell ML, Klein RZ</AU>
<TI>Thyroid function in very low birth weight infants: effects on hypothyroidism screening</TI>
<SO>J Pediatr</SO>
<YR>1996</YR>
<VL>128</VL>
<PG>548-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Franklin-1986" NAME="Franklin 1986" TYPE="JOURNAL_ARTICLE">
<AU>Franklin RC, Purdie GL, O'Grady CM</AU>
<TI>Neonatal thyroid function: prematurity, prenatal steroids, and respiratory distress syndrome</TI>
<SO>Arch Dis Child</SO>
<YR>1986</YR>
<VL>61</VL>
<PG>589-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hempel-1993" NAME="Hempel 1993" NOTES="&lt;p&gt;Hempel MS. The neurological examination for toddler-age. (PhD thesis. Groningen, the Netherlands: Universisty of Groningen, 1993).&lt;/p&gt;" TYPE="BOOK">
<AU>Hempel MS</AU>
<SO>The neurological examination for toddler-age [PhD thesis]</SO>
<YR>1993</YR>
<PB>Universisty of Groningen</PB>
<CY>The Netherlands</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kooistra-1994" NAME="Kooistra 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kooistra L, Laane C, Vulsma T, Schellekens JMH, van der Meere JJ, Kalverboer AF</AU>
<TI>Motor and cognitive development in children with congenital hypothyroidism: a long-term evaluation of the effects of neonatal treatment</TI>
<SO>J Pediatr</SO>
<YR>1994</YR>
<VL>124</VL>
<PG>903-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liggins-1988" NAME="Liggins 1988" TYPE="JOURNAL_ARTICLE">
<AU>Liggins GC, Schellenberg JC, Manzai M, Kitterman JA, Lee CC</AU>
<TI>Synergisms of cortisol and thyrotropin releasing hormone in lung maturation in fetal sheep</TI>
<SO>J Appl Physiol</SO>
<YR>1988</YR>
<VL>65</VL>
<PG>1880-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Linder-1997" NAME="Linder 1997" TYPE="JOURNAL_ARTICLE">
<AU>Linder N, Davidovitch N, Reichman B, Kuint J, Lubin D, Meyerovitch J, Sela BA, Dolfin Z, Sack J</AU>
<TI>Topical iodine-containing antiseptics and subclinical hypothyroidism in preterm infants</TI>
<SO>J Pediatr</SO>
<YR>1997</YR>
<VL>131</VL>
<PG>434-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lorenz-1998" NAME="Lorenz 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lorenz JM, Wooliever DE, Jetton JR, Paneth N</AU>
<TI>A quantitative review of mortality and developmental disability in extremely premature newborns</TI>
<SO>Arch Pediatr Adolesc Med</SO>
<YR>1998</YR>
<VL>152</VL>
<PG>425-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lucas-1988" NAME="Lucas 1988" TYPE="JOURNAL_ARTICLE">
<AU>Lucas A, Rennie J, Baker BA, Morley R</AU>
<TI>Low plasma triiodothyronine and outcome in preterm infants</TI>
<SO>Arch Dis Child</SO>
<YR>1988</YR>
<VL>63</VL>
<PG>1201-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lucas-1996" NAME="Lucas 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lucas A, Morley R, Fewtrell MS</AU>
<TI>Low triiodothyronine concentration in preterm infants and subsequent intelligence quotient (IQ) at 8 year follow up</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>312</VL>
<PG>1132-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meijer-1992" NAME="Meijer 1992" TYPE="JOURNAL_ARTICLE">
<AU>Meijer WJ, Verloove-Vanhorick SP, Brand R, van den Brande JL</AU>
<TI>Transient hypothyroxinaemia associated with developmental delay in very preterm infants</TI>
<SO>Arch Dis Child</SO>
<YR>1992</YR>
<VL>67</VL>
<PG>944-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paneth-1998" NAME="Paneth 1998" TYPE="JOURNAL_ARTICLE">
<AU>Paneth N</AU>
<TI>Does transient thyroxinemia cause abnormal neurodevelopment in premature infants?</TI>
<SO>Clin Perinatol</SO>
<YR>1998</YR>
<VL>25</VL>
<PG>627-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Porterfield-1993" NAME="Porterfield 1993" TYPE="JOURNAL_ARTICLE">
<AU>Porterfield SP, Hendrich CE</AU>
<TI>The role of thyroid hormones in prenatal and neonatal neurological development - current perspectives</TI>
<SO>Endocr Rev</SO>
<YR>1993</YR>
<VL>14</VL>
<PG>94-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Radunovic-1991" NAME="Radunovic 1991" TYPE="JOURNAL_ARTICLE">
<AU>Radunovic N, Dumez Y, Nastic D, Mandelbrot L, Dommergues M</AU>
<TI>Thyroid function in fetus and mother during the second half of normal pregnancy</TI>
<SO>Biol Neonate</SO>
<YR>1991</YR>
<VL>59</VL>
<PG>139-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reuss-1996" NAME="Reuss 1996" TYPE="JOURNAL_ARTICLE">
<AU>Reuss ML, Paneth N, Pinto-Martin JA, Lorenz JM, Susser M</AU>
<TI>The relation of transient hypothyroxinemia in preterm infants to neurologic development at two years of age</TI>
<SO>N Engl J Med</SO>
<YR>1996</YR>
<VL>334</VL>
<PG>821-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reuss-1997" NAME="Reuss 1997" TYPE="JOURNAL_ARTICLE">
<AU>Reuss ML, Leviton A, Paneth N, Susser M</AU>
<TI>Thyroxine values from newborn screening of 919 infants born before 29 weeks' gestation</TI>
<SO>Am J Public Health</SO>
<YR>1997</YR>
<VL>87</VL>
<PG>1693-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rooman-1996" NAME="Rooman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Rooman RP, Du Caju MVL, Op De Beeck, Docx M, Van Acker</AU>
<TI>Low thyroxinaemia occurs in the majority of very preterm newborns</TI>
<SO>Eur J Pediatr</SO>
<YR>1996</YR>
<VL>55</VL>
<PG>211-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorpe_x002d_Beetson-1991" NAME="Thorpe-Beetson 1991" TYPE="JOURNAL_ARTICLE">
<AU>Thorpe-Beetson JG, Nicolaides KH, Felton CV, Butler J, McGregor AM</AU>
<TI>Maturation of the secretion of thyroid hormone and thyroid stimulating hormone in the fetus</TI>
<SO>N Engl J Med</SO>
<YR>1991</YR>
<VL>324</VL>
<PG>532-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Touwen-1976" NAME="Touwen 1976" NOTES="&lt;p&gt;Touwen B. Neurological development in infancy. No. 58 of Clinics in developmental medicine. London: William Heinemann Medical Books, 1976.&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Touwen B</AU>
<TI>Neurological development in infancy</TI>
<SO>Clinics in developmental medicine</SO>
<YR>1976</YR>
<VL>No. 58</VL>
<PB>William Heinemann Medical Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-09-11 14:22:02 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Osborn-1999" MODIFIED="2008-09-11 14:22:02 -0400" MODIFIED_BY="[Empty name]" NAME="Osborn 1999" TYPE="COCHRANE_REVIEW">
<AU>Osborn DA</AU>
<TI>Thyroid hormone for preventing neurodevelopmental impairment in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-09-11 14:21:48 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-11 14:21:48 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001070"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-09-11 14:24:24 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Amato-1989">
<CHAR_METHODS>
<P>Quasi-random study: alternate assignment.<BR/>Single center.<BR/>Blinding of randomization: no.<BR/>Blinding of intervention: not stated.<BR/>Complete follow up: no, 6 (12%) post-randomisation exclusions (3 treatment and 3 controls).<BR/>Blinding of outcome measurement: not stated.<BR/>Power calculation performed: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>Fifty preterm infants &lt; 32 weeks gestation with respiratory distress syndrome diagnosed by presence of respiratory distress and chest x-ray changes.<BR/>FiO2 &gt; 0.4<BR/>No antenatal steroids.<BR/>Exclusion criteria: <BR/>Not respiratory distress syndrome.<BR/>Treatment group: mean birth weight (+/- sd) 1180 +/- 430g, mean gestation 30.1 +/- 1.9 weeks (n = 25).<BR/>Controls: mean birth weight 1210 +/- 380g, mean gestation 29.2 +/- 2.1 weeks (n = 25).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: L-triiodothyronine 50 micrograms/day in 2 divided doses for 2 days IV, commenced day 1.<BR/>Control: no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality to discharge.<BR/>Peak oxygen concentrations.<BR/>Duration mechanical ventilation.<BR/>Development of major complications of RDS: periventricular hemorrrhage, air leak, chronic lung disease (O2 at 28 days), patent ductus arteriosus, necrotizing enterocolitis, retinopathy of prematurity (cicatricial disease only).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chowdhry-1984">
<CHAR_METHODS>
<P>Random study: yes - randomized in pharmacy by "drawing cards".<BR/>Single center.<BR/>Blinding of randomization: yes.<BR/>Blinding of intervention: yes, placebo controlled.<BR/>Complete follow up: no, 15 (65%) lost to neurodevelopmental follow up. All infants had mortality, thyroid function and growth assessed.<BR/>Blinding of outcome measurement: yes.<BR/>Power calculation performed: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Twenty three preterm infants &lt; 1250g and 25-28 weeks' gestation with T4 &lt;= 4 microg/dl and TSH &lt;= 20 IU/L on two occasions.<BR/>Treated group: mean birth weight (+/- sd) 834+/-182g, mean gestation 26.5+/-10.6 weeks (n = 11).<BR/>Control group: mean birth weight 738+/-162g, mean gestation 26.3+/-3.4 weeks (n = 12).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: from day 15, approximately 7 weeks treatment with thyroxine 10 microg/kg/day IM (orally when tolerating feeds). Increased to 15 micrograms/kg/day if no increase in serum T4 after 1 week. <BR/>Controls: placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Neurodevelopment at 12 months: Bayley Mental Development Index and Bayley Psychomotor Index.<BR/>Neonatal mortality.<BR/>Mean time to T4 &gt; 5 microg/dl.<BR/>Weight gain (mean daily weight gain = g/day).<BR/>Growth of head circumference = cm/week.<BR/>Growth of length = cm/week.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Five treated and 3 controls evaluated at 12 months.<BR/>Two treated and 2 control infants evaluated at 24 months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Smith-2000">
<CHAR_METHODS>
<P>Random study: yes, sequentially numbered envelopes in blocks of 8 allocated to individual centres.<BR/>Two centers.<BR/>Blinding of intervention: yes, placebo controlled.<BR/>Complete follow up: no, 2 losses in control (&gt; 32 weeks, thyroid disease).<BR/>Blinding of outcome measurement: probably, but one investigator examined thyroid tests to determine need for thyroid treatment.<BR/>Power calculation performed: yes, 300 needed to detect reduced incidence of oxygen at 28 days from 30 to 15%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Forty nine infants.<BR/>Inclusion criteria: Infants &lt; 32 weeks, birthweight 600-1500g.<BR/>Exclusion criteria: maternal thyroid disease or illicit drug use, infant lethal malformation or congenital thyroid disease.<BR/>Second of twins not enrolled.<BR/>Treatment group: (+/-sd) 28.6 (0.4) weeks gestation, 1074g (46) birthweight (n = 29).<BR/>Control group: 28.8 (0.5) weeks, 1037g (66) birthweight (n = 18, 2 losses).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: IV thyroxine 10 micrograms/kg/day started before 48 hours age. Oral thyroxine 20 microgram/kg/day commenced as soon as oral feedings tolerated.<BR/>Control: placebo (saline).<BR/>Continued for 21 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: oxygen at 28 days.<BR/>Secondary: death before 12 months, intraventricular hemorrhage, periventricular leucomalacia, patent ductus arteriosus, sepsis and necrotizing enterocolitis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study stopped early due to minimal effect seen on oxygen at 28 days.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-van-Wassenaer-1997">
<CHAR_METHODS>
<P>Random study: computerised block (size 10) randomization. Not stratified.<BR/>Single center.<BR/>Blinding of randomization: yes.<BR/>Blinding of intervention: yes, placebo controlled.<BR/>Complete follow up: yes: 96% of survivors had neurodevelopmental followup. Treatment group had 4 losses and control group 3 (congenital abnormality or withdrawn). At 2.7 years, losses were treatment 5 and control 4.<BR/>Blinding of outcome measurement: yes.<BR/>Power calculation performed: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Two hundred preterm infants.<BR/>Inclusion criteria: preterm infants 25-29 weeks.<BR/>Exclusion criteria: severe congenital malformations, maternal endocrine disease or illicit drug use.<BR/>Treatment group: mean birth weight (+/-sd) 1078+/-218g, mean gestation 197+/-8 days (n = 100).<BR/>Controls: mean birth weight 1077+/-239g, mean gestation 196+/-9 days (n = 100).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: thyroxine 8 micrograms/kg daily (IV until tolerating feeds, then oral) for 6 weeks, starting 12-24 hours after birth.<BR/>Control: placebo for 6 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Neurodevelopment at 6 and 12 months (method of Touwen).<BR/>Neurodevelopment at 24 months (method of Hempel).<BR/>Bayley Mental Development Index at 6, 12 and 24 months.<BR/>Bayley Psychomotor Index at 6, 12 and 24 months corrected age. Child Behaviour Checklist (CBCL) for ages 2-3.<BR/>At mean age 5.7 years: Revised Amsterdam Children's Intelligence Test (RAKIT), CBCL and Teacher Report Form (TRF), Movement Assessment Battery for Children and neurologic outcome using method of Touwen (minor neurological dysfunction [MND] and cerebral palsy.<BR/>Mortality (to time of discharge), respiratory distress syndrome, patent ductus arteriosus, intraventricular hemorrhage, <BR/>cerebral ischemic lesions, chronic lung disease (at 36 weeks), retinopathy of prematurity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Subgroup analysis stratified for gestation (24-25 weeks and 26-29 weeks) not prespecified.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vanhole-1997">
<CHAR_METHODS>
<P>Random study: used sealed envelopes.<BR/>Single center.<BR/>Blinding of randomization: yes.<BR/>Blinding of intervention: yes, placebo controlled.<BR/>Complete follow up: yes - all survivors had neurodevelopmental follow up. 6 (15%) neonatal deaths excuded from analysis of neonatal morbidities (CLD and RDS).<BR/>Blinding of outcome measurement: yes.<BR/>Power calculation performed: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Forty preterm infants:<BR/>Inclusion criteria: inborn, gestation 25-30 weeks, cord blood available.<BR/>Exclusion criteria: congenital malformations and maternal thyroid disease.<BR/>Treatment group: mean birth weight (+/- sd) 1191+/-299g, mean gestation 28.4+/-1.7 weeks (n = 20).<BR/>Control group: mean birth weight 1206+/-411g, mean gestation 28.5+/-1.9 weeks (n = 20).<BR/>The mothers of 11/17 of the treatment group and 13/17 of controls received antenatal steroids and TRH.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: thyroxine 20 microgram/kg/day IV for two weeks from day 1.<BR/>Control: placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean Bayley Mental Development Index at 7 months corrected age<BR/>Mean Bayley Psychomotor Index at 7 months corrected age<BR/>Neonatal mortality<BR/>Respiratory distress syndrome<BR/>Chronic lung disease (oxygen at 28 days and CXR changes)<BR/>Heart rate, daily inspired oxygen, weekly weight gain, and enteral fluid intake</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Also evaluated thyroid hormone (T4, T3 and reverse T3), prolactin and growth hormone levels in infants and effects of dopamine infusions.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Amato-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Inadequate randomisation performed. Used alternate assignment and excluded 25% after trial entry as they did not have respiratory distress syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eggermont-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized cohort comparison. Thyroxine given to 'sick' preterm infants and compared to a control group of 'non-sick' preterm infants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schonberger-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Inadequate randomisation. Used alternation and included 5 infants who were not alternated as controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Wassenaer-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised study. Used historical controls to compare the effect of three different doses of thyroxine on neonatal thyroid hormone levels. Dose was varied over 3 consecutive time periods (6, 8 and 10 micrograms/kg/day).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-09-11 14:24:24 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2008-09-11 14:24:24 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-THORN">
<CHAR_METHODS MODIFIED="2008-09-11 14:24:13 -0400" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-11 14:24:20 -0400" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-11 14:24:21 -0400" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-11 14:24:24 -0400" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Golombek">
<CHAR_STUDY_NAME>
<P>Hypothyroxemia trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Very preterm infants (&lt;28 weeks)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Thyroid hormones - type and dose to be determined</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Include neurodevelopment</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>To be announced</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>SERGIO_GOLOMBECK@NYMC.EDU</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Amato-1989">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Chowdhry-1984">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Smith-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Vanhole-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-van-Wassenaer-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Thyroid hormones versus control (All eligible studies)</NAME>
<DICH_OUTCOME CHI2="6.514243491816024E-5" CI_END="1.3051552666582436" CI_START="0.3375171908632051" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6637110359507424" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.11566218021206043" LOG_CI_START="-0.4717041022199355" LOG_EFFECT_SIZE="-0.17802096100393752" METHOD="MH" NO="1" P_CHI2="0.9935602747284679" P_Q="0.0" P_Z="0.23480780884636065" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="163" TOTAL_2="150" WEIGHT="200.0" Z="1.188065037088075">
<NAME>Abnormal mental development in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5643946728730251" CI_START="0.2828414775261446" DF="0.0" EFFECT_SIZE="0.6651884700665188" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.19434632840909546" LOG_CI_START="-0.5484569027256916" LOG_EFFECT_SIZE="-0.1770552871582981" NO="1" P_CHI2="1.0" P_Z="0.35011938373468743" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="75" WEIGHT="100.0" Z="0.9343577721720807">
<NAME>MDI &gt; 2sd below mean at 2 years</NAME>
<DICH_DATA CI_END="1.5643946728730251" CI_START="0.2828414775261446" EFFECT_SIZE="0.6651884700665188" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.19434632840909546" LOG_CI_START="-0.5484569027256916" LOG_EFFECT_SIZE="-0.1770552871582981" ORDER="88544" O_E="0.0" SE="0.436326294903869" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="82" TOTAL_2="75" VAR="0.19038063562453805" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9944940458402012" CI_START="0.21931264541620968" DF="0.0" EFFECT_SIZE="0.6613756613756614" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.29983274414919014" LOG_CI_START="-0.6589363264795656" LOG_EFFECT_SIZE="-0.1795517911651877" NO="2" P_CHI2="1.0" P_Z="0.4628892526767646" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="75" WEIGHT="100.0" Z="0.7340976150026219">
<NAME>IQ &gt; 2sd below mean at 5 years</NAME>
<DICH_DATA CI_END="1.9944940458402012" CI_START="0.21931264541620968" EFFECT_SIZE="0.6613756613756614" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.29983274414919014" LOG_CI_START="-0.6589363264795656" LOG_EFFECT_SIZE="-0.1795517911651877" ORDER="88545" O_E="0.0" SE="0.563185698070773" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="81" TOTAL_2="75" VAR="0.3171781305114639" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8370994500740876" CI_START="0.28231300385630276" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.720164609053498" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.26413266716554334" LOG_CI_START="-0.5492691169895788" LOG_EFFECT_SIZE="-0.1425682249120177" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.4920438840290349" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="75" WEIGHT="100.00000000000001" Z="0.6870616504919582">
<NAME>Cerebral palsy in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8370994500740878" CI_START="0.28231300385630276" EFFECT_SIZE="0.720164609053498" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.2641326671655434" LOG_CI_START="-0.5492691169895788" LOG_EFFECT_SIZE="-0.1425682249120177" ORDER="88546" O_E="0.0" SE="0.4777962344164874" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="81" TOTAL_2="75" VAR="0.22828924162257494" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.8864740914306593" CI_END="3.185712170108144" CI_START="-5.462639452063789" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1384636409778226" ESTIMABLE="YES" I2="65.35565647483925" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.08932635342977402" P_Q="1.0" P_Z="0.6058426180220282" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="92" UNITS="" WEIGHT="100.0" Z="0.5160168854153259">
<NAME>Bayley MDI at 7-12 months in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.208332309204903" CI_START="-11.208332309204902" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="97.0" MEAN_2="102.0" ORDER="1" SD_1="12.4" SD_2="4.1" SE="3.167574689216453" STUDY_ID="STD-Vanhole-1997" TOTAL_1="17" TOTAL_2="17" WEIGHT="48.51284854637097"/>
<CONT_DATA CI_END="8.52634388649482" CI_START="-3.5263438864948196" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="106.5" MEAN_2="104.0" ORDER="88548" SD_1="18.5" SD_2="19.9" SE="3.074721746945276" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="82" TOTAL_2="75" WEIGHT="51.48715145362903"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.198651971777403" CI_END="5.239302131010049" CI_START="-4.8039466463087255" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.21767774235066203" ESTIMABLE="YES" I2="76.18283185360866" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.04045626488862719" P_Q="1.0" P_Z="0.9322926643134881" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="92" UNITS="" WEIGHT="100.0" Z="0.08496066257101842">
<NAME>Bayley PDI at 7-12 months in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.0798886633544926" CI_START="-12.079888663354492" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="88.0" MEAN_2="93.0" ORDER="1" SD_1="12.4" SD_2="8.25" SE="3.612254469571763" STUDY_ID="STD-Vanhole-1997" TOTAL_1="17" TOTAL_2="17" WEIGHT="50.30783102523179"/>
<CONT_DATA CI_END="12.623611858955789" CI_START="-1.6236118589557886" EFFECT_SIZE="5.5" ESTIMABLE="YES" MEAN_1="98.3" MEAN_2="92.8" ORDER="88550" SD_1="22.8" SD_2="22.7" SE="3.634562632347293" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="82" TOTAL_2="75" WEIGHT="49.692168974768215"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.208062794298819" CI_START="-11.208062794298819" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.3734869298140999" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="75" UNITS="" WEIGHT="99.99999999999999" Z="0.8899608278962151">
<NAME>Bayley MDI at 24 months in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.208062794298819" CI_START="-11.208062794298819" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="93.2" MEAN_2="96.7" ORDER="88551" SD_1="22.5" SD_2="26.4" SE="3.9327573644715077" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="82" TOTAL_2="75" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.509856743884855" CI_START="-3.3098567438848665" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.0999999999999943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.34318155649402815" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="75" UNITS="" WEIGHT="99.99999999999999" Z="0.9478976824046315">
<NAME>Bayley PDI at 24 months in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.509856743884855" CI_START="-3.3098567438848665" EFFECT_SIZE="3.0999999999999943" ESTIMABLE="YES" MEAN_1="89.3" MEAN_2="86.2" ORDER="88552" SD_1="20.1" SD_2="20.8" SE="3.270395167689301" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="82" TOTAL_2="75" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.7104916559028327" CI_START="-7.91049165590285" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.1000000000000085" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.47872125026583867" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="75" UNITS="" WEIGHT="100.0" Z="0.7083607741442653">
<NAME>RAKIT IQ score at 5 years in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.7104916559028327" CI_START="-7.91049165590285" EFFECT_SIZE="-2.1000000000000085" ESTIMABLE="YES" MEAN_1="93.6" MEAN_2="95.7" ORDER="88553" SD_1="16.2" SD_2="20.4" SE="2.964591034190045" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="81" TOTAL_2="75" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.6082872913092627" CI_END="1.1357293347066744" CI_START="0.36427832060751303" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6432119205298013" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.055274843303516896" LOG_CI_START="-0.4385666742719144" LOG_EFFECT_SIZE="-0.1916459154841988" METHOD="MH" NO="8" P_CHI2="0.7377549201817581" P_Q="0.0" P_Z="0.12820636989590675" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="150" WEIGHT="100.0" Z="1.5212130967739592">
<NAME>Neonatal mortality</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.372816405310655" CI_START="0.22868556722059719" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6407612436759104" LOG_CI_START="-0.6407612436759105" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.7527726527090809" STUDY_ID="STD-Vanhole-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.5666666666666665" WEIGHT="11.672185430463577"/>
<DICH_DATA CI_END="2.2420376701575746" CI_START="0.07637014076098082" EFFECT_SIZE="0.41379310344827586" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.3506429052277895" LOG_CI_START="-1.1170764089304521" LOG_EFFECT_SIZE="-0.38321675185133125" ORDER="88555" O_E="0.0" SE="0.8621455904643299" STUDY_ID="STD-Smith-2000" TOTAL_1="29" TOTAL_2="18" VAR="0.7432950191570881" WEIGHT="14.403973509933774"/>
<DICH_DATA CI_END="1.2310979128206556" CI_START="0.3240131939181613" EFFECT_SIZE="0.631578947368421" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.09029259501635631" LOG_CI_START="-0.4894373048267646" LOG_EFFECT_SIZE="-0.19957235490520417" ORDER="88557" O_E="0.0" SE="0.3405362128771355" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="100" TOTAL_2="100" VAR="0.11596491228070173" WEIGHT="73.92384105960265"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8678496561770049" CI_END="1.1659395297778943" CI_START="0.42475194067945116" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7037294067950034" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.06667602678252305" LOG_CI_START="-0.37186462817533505" LOG_EFFECT_SIZE="-0.15259430069640598" METHOD="MH" NO="9" P_CHI2="0.9291273324317417" P_Q="0.0" P_Z="0.17257530676367502" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="172" WEIGHT="100.00000000000001" Z="1.3639754044685837">
<NAME>Mortality to discharge</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.480206230341023" CI_START="0.15431607644181022" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8115888273634806" LOG_CI_START="-0.8115888273634805" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.9534625892455924" STUDY_ID="STD-Amato-1989" TOTAL_1="22" TOTAL_2="22" VAR="0.9090909090909092" WEIGHT="6.523444571842376"/>
<DICH_DATA CI_END="1.2353711589146819" CI_START="0.35976592236045474" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.09179745804229697" LOG_CI_START="-0.4439799761536595" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="2" O_E="0.0" SE="0.31471831698777725" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="100" TOTAL_2="100" VAR="0.09904761904761905" WEIGHT="68.49616800434495"/>
<DICH_DATA CI_END="4.372816405310655" CI_START="0.22868556722059719" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6407612436759104" LOG_CI_START="-0.6407612436759105" LOG_EFFECT_SIZE="0.0" ORDER="4" O_E="0.0" SE="0.7527726527090809" STUDY_ID="STD-Vanhole-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.5666666666666665" WEIGHT="9.785166857763564"/>
<DICH_DATA CI_END="15.414774237929704" CI_START="0.077204026880898" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.187937168508564" LOG_CI_START="-1.1123600467297645" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="88559" O_E="0.0" SE="1.3512059708858513" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" VAR="1.825757575757576" WEIGHT="3.119908273489832"/>
<DICH_DATA CI_END="2.2420376701575746" CI_START="0.07637014076098082" EFFECT_SIZE="0.41379310344827586" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.3506429052277895" LOG_CI_START="-1.1170764089304521" LOG_EFFECT_SIZE="-0.38321675185133125" ORDER="88560" O_E="0.0" SE="0.8621455904643299" STUDY_ID="STD-Smith-2000" TOTAL_1="29" TOTAL_2="18" VAR="0.7432950191570881" WEIGHT="12.07531229255929"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1356571496403007" CI_START="0.431468247397728" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.05524723939178414" LOG_CI_START="-0.3650511593632706" LOG_EFFECT_SIZE="-0.1549019599857432" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.14854255186254986" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="1.4446986408038034">
<NAME>Death or cerebral palsy</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1356571496403007" CI_START="0.431468247397728" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="0.05524723939178414" LOG_CI_START="-0.3650511593632706" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="1" O_E="0.0" SE="0.24688535993934704" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="100" TOTAL_2="100" VAR="0.060952380952380945" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9673888954995804" CI_START="0.1895605934406179" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.47237446714650794" LOG_CI_START="-0.7222519403631077" LOG_EFFECT_SIZE="-0.12493873660829993" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.6818341823470917" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="0.40996151179461165">
<NAME>Air leak</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9673888954995804" CI_START="0.1895605934406179" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.47237446714650794" LOG_CI_START="-0.7222519403631077" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="1" O_E="0.0" SE="0.701729465267237" STUDY_ID="STD-Amato-1989" TOTAL_1="22" TOTAL_2="22" VAR="0.4924242424242424" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.8513551833994586" CI_END="0.5330988788056295" CI_START="-5.41105728350237" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.43897920234837" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" NO="12" P_CHI2="0.653326964530174" P_Q="1.0" P_Z="0.10774605445099297" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="54" UNITS="" WEIGHT="100.0" Z="1.6084070690999253">
<NAME>Duration of mechanical ventilation (days)</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0459489532134318" CI_START="-5.245948953213431" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="14.6" ORDER="1" SD_1="5.8" SD_2="4.8" SE="1.605105490727521" STUDY_ID="STD-Amato-1989" TOTAL_1="22" TOTAL_2="22" WEIGHT="89.25182122956369"/>
<CONT_DATA CI_END="5.799093556186714" CI_START="-13.799093556186714" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="14.0" ORDER="2" SD_1="12.37" SD_2="16.49" SE="4.999629398030123" STUDY_ID="STD-Vanhole-1997" TOTAL_1="17" TOTAL_2="17" WEIGHT="9.199169509400901"/>
<CONT_DATA CI_END="11.179938704209484" CI_START="-36.57993870420948" EFFECT_SIZE="-12.7" ESTIMABLE="YES" MEAN_1="27.8" MEAN_2="40.5" ORDER="88566" SD_1="33.8" SD_2="39.9" SE="12.183866077423561" STUDY_ID="STD-Smith-2000" TOTAL_1="27" TOTAL_2="15" WEIGHT="1.5490092610354065"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.5055821993241895" CI_END="1.2272153802223877" CI_START="0.7535468520163897" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9616466536689435" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="66" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.08892078948614528" LOG_CI_START="-0.1228897401116419" LOG_EFFECT_SIZE="-0.016984475312748323" METHOD="MH" NO="13" P_CHI2="0.9729552914768008" P_Q="0.0" P_Z="0.7532721509789477" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="163" TOTAL_2="145" WEIGHT="100.0" Z="0.3143277151755363">
<NAME>CLD in survivors (oxygen at 28 days)</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9227329034845608" CI_START="0.45474149384109297" EFFECT_SIZE="0.935064935064935" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.28391895839376385" LOG_CI_START="-0.3422354158761907" LOG_EFFECT_SIZE="-0.029158228741213422" ORDER="1" O_E="0.0" SE="0.3678061789603123" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" VAR="0.13528138528138528" WEIGHT="9.6493527886048"/>
<DICH_DATA CI_END="2.0086608078120443" CI_START="0.2212640594748102" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3029066058709399" LOG_CI_START="-0.6550891239823023" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="2" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Amato-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="8.646822628749755"/>
<DICH_DATA CI_END="1.642958312138172" CI_START="0.6086581702116253" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.2156265439353387" LOG_CI_START="-0.2156265439353387" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.25332019855244947" STUDY_ID="STD-Vanhole-1997" TOTAL_1="17" TOTAL_2="17" VAR="0.06417112299465241" WEIGHT="15.852508152707882"/>
<DICH_DATA CI_END="1.76588683009749" CI_START="0.5352642271705108" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.24696286762261133" LOG_CI_START="-0.27143178045663463" LOG_EFFECT_SIZE="-0.012234456417011635" ORDER="88570" O_E="0.0" SE="0.3045075823766425" STUDY_ID="STD-Smith-2000" TOTAL_1="27" TOTAL_2="15" VAR="0.09272486772486772" WEIGHT="14.823124506428151"/>
<DICH_DATA CI_END="1.4279680518090982" CI_START="0.7026382959830414" EFFECT_SIZE="1.0016711229946524" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="34" LOG_CI_END="0.1547184909988199" LOG_CI_START="-0.15326818349237786" LOG_EFFECT_SIZE="7.251537532210107E-4" ORDER="88572" O_E="0.0" SE="0.18091289715475606" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="88" TOTAL_2="81" VAR="0.03272947635692734" WEIGHT="51.028191923509404"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2859311163892346" CI_END="1.644057606904657" CI_START="0.6378617457329852" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.024051490514905" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.21591703091844275" LOG_CI_START="-0.19527344286481663" LOG_EFFECT_SIZE="0.010321794026813068" METHOD="MH" NO="14" P_CHI2="0.5257310530945376" P_Q="0.0" P_Z="0.9216155504674397" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="117" TOTAL_2="110" WEIGHT="99.99999999999999" Z="0.09839889704768691">
<NAME>CLD in survivors (oxygen at 36 weeks)</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5705924916828753" CI_START="0.14813385203345344" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.552740287405811" LOG_CI_START="-0.8293456837383739" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="1" O_E="0.0" SE="0.8118441408859887" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" VAR="0.659090909090909" WEIGHT="11.178861788617885"/>
<DICH_DATA CI_END="1.6601956347279412" CI_START="0.49891981985751127" EFFECT_SIZE="0.9101123595505618" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.2201592676043092" LOG_CI_START="-0.30196924313683526" LOG_EFFECT_SIZE="-0.040904987766263036" ORDER="2" O_E="0.0" SE="0.30670087178716" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="89" TOTAL_2="81" VAR="0.09406542475500396" WEIGHT="69.34281842818427"/>
<DICH_DATA CI_END="3.9059197408280344" CI_START="0.6554154129796055" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5917233151234644" LOG_CI_START="-0.18348334981161493" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="3" O_E="0.0" SE="0.45536023231774486" STUDY_ID="STD-Vanhole-1997" TOTAL_1="17" TOTAL_2="17" VAR="0.20735294117647057" WEIGHT="19.47831978319783"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3887767555672519" CI_END="1.03499116254794" CI_START="0.5645932083887235" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7644272242122963" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.014936641509796794" LOG_CI_START="-0.24826435037797828" LOG_EFFECT_SIZE="-0.11666385443409075" METHOD="MH" NO="15" P_CHI2="0.8461433616071986" P_Q="0.0" P_Z="0.08229749160434251" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="172" WEIGHT="100.0" Z="1.7375082924150773">
<NAME>Patent ductus arteriosus</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5586207671985255" CI_START="0.2493219792463754" EFFECT_SIZE="0.6233766233766234" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.1927404585191259" LOG_CI_START="-0.6032394341129154" LOG_EFFECT_SIZE="-0.20524948779689467" ORDER="1" O_E="0.0" SE="0.4675625290960757" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" VAR="0.21861471861471865" WEIGHT="10.582644930184955"/>
<DICH_DATA CI_END="2.6064627627310486" CI_START="0.5011091919882401" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4160515247527956" LOG_CI_START="-0.3000676307974221" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="2" O_E="0.0" SE="0.42065193681718843" STUDY_ID="STD-Amato-1989" TOTAL_1="22" TOTAL_2="22" VAR="0.1769480519480519" WEIGHT="11.063674245193361"/>
<DICH_DATA CI_END="1.1801649524439484" CI_START="0.444324110860093" EFFECT_SIZE="0.7241379310344828" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="29" LOG_CI_END="0.07194271317859051" LOG_CI_START="-0.3523001195086642" LOG_EFFECT_SIZE="-0.1401787031650368" ORDER="3" O_E="0.0" SE="0.2492023399563842" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="100" TOTAL_2="100" VAR="0.062101806239737274" WEIGHT="45.835221872943926"/>
<DICH_DATA CI_END="2.102230118933325" CI_START="0.3494830898549799" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.32268025399138267" LOG_CI_START="-0.45657383325260914" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="4" O_E="0.0" SE="0.4577377082170635" STUDY_ID="STD-Vanhole-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.20952380952380956" WEIGHT="11.063674245193361"/>
<DICH_DATA CI_END="1.1958157223587205" CI_START="0.38340862383936614" EFFECT_SIZE="0.677115987460815" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.07766425914329422" LOG_CI_START="-0.41633812295579475" LOG_EFFECT_SIZE="-0.16933693190625024" ORDER="88578" O_E="0.0" SE="0.29017944459623435" STUDY_ID="STD-Smith-2000" TOTAL_1="29" TOTAL_2="18" VAR="0.08420411006617903" WEIGHT="21.454784706484393"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1709114155478381" CI_END="1.6290525154092146" CI_START="0.877555577527762" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1956521739130435" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.21193508479028852" LOG_CI_START="-0.056725369164949" LOG_EFFECT_SIZE="0.07760485781266976" METHOD="MH" NO="16" P_CHI2="0.9180938419415064" P_Q="0.0" P_Z="0.2575064393172718" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="142" WEIGHT="99.99999999999999" Z="1.1323045435151908">
<NAME>Intraventricular hemorrhage - any grade</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.275358036443697" CI_START="0.3369966105610984" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7222519403631077" LOG_CI_START="-0.4723744671465079" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="1" O_E="0.0" SE="0.701729465267237" STUDY_ID="STD-Amato-1989" TOTAL_1="22" TOTAL_2="22" VAR="0.4924242424242424" WEIGHT="6.521739130434782"/>
<DICH_DATA CI_END="1.7005397330106575" CI_START="0.8698308283385577" EFFECT_SIZE="1.2162162162162162" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="37" LOG_CI_END="0.23058678365226676" LOG_CI_START="-0.060565204235569395" LOG_EFFECT_SIZE="0.08501078970834869" ORDER="2" O_E="0.0" SE="0.1710241189108988" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="100" TOTAL_2="100" VAR="0.02924924924924925" WEIGHT="80.43478260869564"/>
<DICH_DATA CI_END="2.577326316861588" CI_START="0.38799898695703405" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4111694083221442" LOG_CI_START="-0.4111694083221443" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.48304589153964794" STUDY_ID="STD-Vanhole-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.23333333333333334" WEIGHT="13.043478260869565"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6080602544743929" CI_END="2.1070423168642245" CI_START="0.5469588288283719" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0735294117647058" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.32367325786537376" LOG_CI_START="-0.2620453630369346" LOG_EFFECT_SIZE="0.030813947414219566" METHOD="MH" NO="17" P_CHI2="0.7378386736103155" P_Q="0.0" P_Z="0.8366169852061435" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="149" TOTAL_2="138" WEIGHT="99.99999999999999" Z="0.20622266391443478">
<NAME>Intraventricular hemorrhage - grade 3 or 4</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3555210007077925" CI_START="0.5052311757231204" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.37208698055508593" LOG_CI_START="-0.29650985877628644" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="1" O_E="0.0" SE="0.3927370930309795" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="100" TOTAL_2="100" VAR="0.15424242424242424" WEIGHT="76.02941176470587"/>
<DICH_DATA CI_END="20.332240770599807" CI_START="0.19673188238966538" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3081852438953019" LOG_CI_START="-0.7061252525673394" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="2" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-Vanhole-1997" TOTAL_1="20" TOTAL_2="20" VAR="1.4" WEIGHT="6.911764705882352"/>
<DICH_DATA CI_END="4.025797571096211" CI_START="0.09569672623483308" EFFECT_SIZE="0.6206896551724138" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.6048519335019311" LOG_CI_START="-1.019102919093231" LOG_EFFECT_SIZE="-0.20712549279564998" ORDER="88584" O_E="0.0" SE="0.953919119120565" STUDY_ID="STD-Smith-2000" TOTAL_1="29" TOTAL_2="18" VAR="0.9099616858237548" WEIGHT="17.058823529411764"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2473067882274047" CI_END="4.381010833949884" CI_START="0.1617215130230189" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.841726618705036" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="19.82726227112592" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.6415743271610181" LOG_CI_START="-0.791232204176885" LOG_EFFECT_SIZE="-0.07482893850793344" METHOD="MH" NO="18" P_CHI2="0.2640675770727756" P_Q="0.0" P_Z="0.8377909505164745" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="118" WEIGHT="100.00000000000003" Z="0.2047199273163059">
<NAME>Periventricular leukomalacia</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.705078767310894" CI_START="0.18428866547235168" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3365613662238505" LOG_CI_START="-0.7345013748958881" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1" O_E="0.0" SE="1.2165525060596438" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="100" TOTAL_2="100" VAR="1.48" WEIGHT="35.251798561151084"/>
<DICH_DATA CI_END="4.91959271229015" CI_START="0.00905926645578366" EFFECT_SIZE="0.2111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6919291494895758" LOG_CI_START="-2.0429069664625676" LOG_EFFECT_SIZE="-0.6754889084864959" ORDER="88587" O_E="0.0" SE="1.6064562721673954" STUDY_ID="STD-Smith-2000" TOTAL_1="29" TOTAL_2="18" VAR="2.5807017543859647" WEIGHT="64.74820143884894"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0012599467709716876" CI_END="3.1615453851958715" CI_START="0.03807204999053415" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3469387755102041" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.4998994206577458" LOG_CI_START="-1.4193937379582253" LOG_EFFECT_SIZE="-0.45974715865023974" METHOD="MH" NO="19" P_CHI2="0.9716844550615541" P_Q="0.0" P_Z="0.3477415978016646" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="34" WEIGHT="100.00000000000001" Z="0.9389788828288007">
<NAME>Necrotizing enterocolitis</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.039573882065785" CI_START="0.016219918677380755" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.905233030642515" LOG_CI_START="-1.7899513275634158" LOG_EFFECT_SIZE="-0.4423591484604505" ORDER="1" O_E="0.0" SE="1.583164633387904" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" VAR="2.506410256410256" WEIGHT="48.9795918367347"/>
<DICH_DATA CI_END="7.763080139825827" CI_START="0.014312761057443371" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8900340694951818" LOG_CI_START="-1.8442765789345066" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="2" O_E="0.0" SE="1.6061476099435992" STUDY_ID="STD-Amato-1989" TOTAL_1="22" TOTAL_2="22" VAR="2.5797101449275357" WEIGHT="51.020408163265316"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.13188436324815134" CI_END="1.7771146824613075" CI_START="0.486026559358642" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.929368029739777" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.24971545501577957" LOG_CI_START="-0.3133399976765203" LOG_EFFECT_SIZE="-0.03181227133037037" METHOD="MH" NO="20" P_CHI2="0.936185001257929" P_Q="0.0" P_Z="0.8247238370449914" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="117" TOTAL_2="113" WEIGHT="100.0" Z="0.22147341181336805">
<NAME>Retinopathy of prematurity (any grade) in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5705924916828753" CI_START="0.14813385203345344" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.552740287405811" LOG_CI_START="-0.8293456837383739" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="1" O_E="0.0" SE="0.8118441408859887" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" VAR="0.659090909090909" WEIGHT="24.11710037174721"/>
<DICH_DATA CI_END="2.0401873360943665" CI_START="0.49015106716344514" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.3096700474732594" LOG_CI_START="-0.3096700474732594" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.3638034375544994" STUDY_ID="STD-Vanhole-1997" TOTAL_1="17" TOTAL_2="17" VAR="0.13235294117647056" WEIGHT="67.23555255153768"/>
<DICH_DATA CI_END="14.84860645757795" CI_START="0.05999193386489131" EFFECT_SIZE="0.9438202247191011" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.171685697007932" LOG_CI_START="-1.221907138173994" LOG_EFFECT_SIZE="-0.025110720583031137" ORDER="88593" O_E="0.0" SE="1.4060082798614872" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="89" TOTAL_2="84" VAR="1.9768592830390583" WEIGHT="8.647347076715107"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9785157472630552" CI_START="0.2635608162040911" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5078369905956113" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="-0.009432180844590111" LOG_CI_START="-0.5791191561845103" LOG_EFFECT_SIZE="-0.29427566851455017" METHOD="MH" NO="21" P_CHI2="1.0" P_Q="0.0" P_Z="0.04288119120075604" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="18" WEIGHT="100.0" Z="2.0248653621432005">
<NAME>Sepsis</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9785157472630552" CI_START="0.2635608162040911" EFFECT_SIZE="0.5078369905956113" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="-0.009432180844590111" LOG_CI_START="-0.5791191561845103" LOG_EFFECT_SIZE="-0.29427566851455017" ORDER="88594" O_E="0.0" SE="0.33463694931067733" STUDY_ID="STD-Smith-2000" TOTAL_1="29" TOTAL_2="18" VAR="0.11198188784395682" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.5658529365102396" CI_START="-2.5458529365102436" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.509999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.22" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.743589248553566" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.3271039715860599">
<NAME>Weight gain (grams/day)</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.5658529365102396" CI_START="-2.5458529365102436" EFFECT_SIZE="0.509999999999998" ESTIMABLE="YES" MEAN_1="16.08" MEAN_2="15.57" ORDER="1" SD_1="4.3" SD_2="3.0" SE="1.5591372905902452" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.1875896844445128" CI_START="-0.14758968444451276" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.23" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.81506237020121" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.23390031326050736">
<NAME>Growth head circumference (cm/week)</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1875896844445128" CI_START="-0.14758968444451276" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="0.78" MEAN_2="0.76" ORDER="1" SD_1="0.2" SD_2="0.21" SE="0.08550651224534676" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.1212705819964073" CI_START="-0.2412705819964072" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.05999999999999994" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.24" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.516505159110914" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.6487419954040525">
<NAME>Growth length (cm/week)</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1212705819964073" CI_START="-0.2412705819964072" EFFECT_SIZE="-0.05999999999999994" ESTIMABLE="YES" MEAN_1="0.67" MEAN_2="0.73" ORDER="1" SD_1="0.26" SD_2="0.17" SE="0.09248669027913087" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.47085553142950404" CI_END="1.5655594044751218" CI_START="0.6734515025429455" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.026804914900591" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="0.1946695513820448" LOG_CI_START="-0.17169367378857575" LOG_EFFECT_SIZE="0.011487938796734536" METHOD="MH" NO="25" P_CHI2="0.7902327493198378" P_Q="0.0" P_Z="0.9021736362828676" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="227" TOTAL_2="208" WEIGHT="300.0" Z="0.12291597382741733">
<NAME>Clinically significant behavioural problems in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormones</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0510002531131397E-31" CI_END="1.8634384992398578" CI_START="0.34798505758420367" DF="0.0" EFFECT_SIZE="0.8052631578947369" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="100.0" ID="CMP-001.25.01" LOG_CI_END="0.27031506390954413" LOG_CI_START="-0.45843940418000434" LOG_EFFECT_SIZE="-0.09406217013523012" NO="1" P_CHI2="0.0" P_Z="0.6128882764110803" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="68" WEIGHT="100.00000000000001" Z="0.5059549514832653">
<NAME>Clinically significant CBCL score at 2 years</NAME>
<DICH_DATA CI_END="1.8634384992398574" CI_START="0.3479850575842036" EFFECT_SIZE="0.8052631578947368" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.270315063909544" LOG_CI_START="-0.4584394041800044" LOG_EFFECT_SIZE="-0.09406217013523017" ORDER="88598" O_E="0.0" SE="0.4280739819485971" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="76" TOTAL_2="68" VAR="0.1832473340213278" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.402748537090048" CI_START="0.5706082338662024" DF="0.0" EFFECT_SIZE="1.170909090909091" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" ID="CMP-001.25.02" LOG_CI_END="0.38070832150356637" LOG_CI_START="-0.24366196577242985" LOG_EFFECT_SIZE="0.06852317786556826" NO="2" P_CHI2="1.0" P_Z="0.6670480384931041" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="69" WEIGHT="100.0" Z="0.4302029211181178">
<NAME>Clinically significant CBCL score at 5 years</NAME>
<DICH_DATA CI_END="2.402748537090048" CI_START="0.5706082338662024" EFFECT_SIZE="1.170909090909091" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.38070832150356637" LOG_CI_START="-0.24366196577242985" LOG_EFFECT_SIZE="0.06852317786556826" ORDER="88599" O_E="0.0" SE="0.36675819742868815" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="75" TOTAL_2="69" VAR="0.13451157538114059" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1034644598482335" CI_START="0.5523955200844749" DF="0.0" EFFECT_SIZE="1.0779352226720649" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" I2="0.0" ID="CMP-001.25.03" LOG_CI_END="0.32293517857208265" LOG_CI_START="-0.2577498521978258" LOG_EFFECT_SIZE="0.032592663187128446" NO="3" P_CHI2="1.0" P_Z="0.8258574945647601" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="71" WEIGHT="100.0" Z="0.2200175400503076">
<NAME>Clinically significant TRF score at 5 years</NAME>
<DICH_DATA CI_END="2.1034644598482335" CI_START="0.5523955200844748" EFFECT_SIZE="1.0779352226720649" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.32293517857208265" LOG_CI_START="-0.25774985219782587" LOG_EFFECT_SIZE="0.032592663187128446" ORDER="88600" O_E="0.0" SE="0.34109726151150493" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="76" TOTAL_2="71" VAR="0.11634734181064797" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Thyroid hormones as prophylaxis (started &lt; 24 hours age in all studies)</NAME>
<DICH_OUTCOME CHI2="6.514243491816024E-5" CI_END="1.3051552666582436" CI_START="0.3375171908632051" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6637110359507424" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.11566218021206043" LOG_CI_START="-0.4717041022199355" LOG_EFFECT_SIZE="-0.17802096100393752" METHOD="MH" NO="1" P_CHI2="0.9935602747284679" P_Q="0.0" P_Z="0.23480780884636065" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="163" TOTAL_2="150" WEIGHT="200.0" Z="1.188065037088075">
<NAME>Abnormal mental development in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5643946728730251" CI_START="0.2828414775261446" DF="0.0" EFFECT_SIZE="0.6651884700665188" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.19434632840909546" LOG_CI_START="-0.5484569027256916" LOG_EFFECT_SIZE="-0.1770552871582981" NO="1" P_CHI2="1.0" P_Z="0.35011938373468743" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="75" WEIGHT="100.0" Z="0.9343577721720807">
<NAME>MDI &gt; 2sd below mean at 2 years</NAME>
<DICH_DATA CI_END="1.5643946728730251" CI_START="0.2828414775261446" EFFECT_SIZE="0.6651884700665188" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.19434632840909546" LOG_CI_START="-0.5484569027256916" LOG_EFFECT_SIZE="-0.1770552871582981" ORDER="88601" O_E="0.0" SE="0.436326294903869" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="82" TOTAL_2="75" VAR="0.19038063562453805" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9944940458402012" CI_START="0.21931264541620968" DF="0.0" EFFECT_SIZE="0.6613756613756614" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.29983274414919014" LOG_CI_START="-0.6589363264795656" LOG_EFFECT_SIZE="-0.1795517911651877" NO="2" P_CHI2="1.0" P_Z="0.4628892526767646" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="75" WEIGHT="100.0" Z="0.7340976150026219">
<NAME>IQ &gt; 2sd below mean at 5 years</NAME>
<DICH_DATA CI_END="1.9944940458402012" CI_START="0.21931264541620968" EFFECT_SIZE="0.6613756613756614" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.29983274414919014" LOG_CI_START="-0.6589363264795656" LOG_EFFECT_SIZE="-0.1795517911651877" ORDER="88602" O_E="0.0" SE="0.563185698070773" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="81" TOTAL_2="75" VAR="0.3171781305114639" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8370994500740876" CI_START="0.28231300385630276" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.720164609053498" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.26413266716554334" LOG_CI_START="-0.5492691169895788" LOG_EFFECT_SIZE="-0.1425682249120177" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.4920438840290349" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="75" WEIGHT="100.00000000000001" Z="0.6870616504919582">
<NAME>Cerebral palsy in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8370994500740878" CI_START="0.28231300385630276" EFFECT_SIZE="0.720164609053498" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.2641326671655434" LOG_CI_START="-0.5492691169895788" LOG_EFFECT_SIZE="-0.1425682249120177" ORDER="88603" O_E="0.0" SE="0.4777962344164874" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="81" TOTAL_2="75" VAR="0.22828924162257494" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.8864740914306593" CI_END="3.185712170108144" CI_START="-5.462639452063789" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1384636409778226" ESTIMABLE="YES" I2="65.35565647483925" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="0.08932635342977402" P_Q="1.0" P_Z="0.6058426180220282" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="92" UNITS="" WEIGHT="100.0" Z="0.5160168854153259">
<NAME>Bayley MDI at 7-12 months in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.208332309204903" CI_START="-11.208332309204902" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="97.0" MEAN_2="102.0" ORDER="1" SD_1="12.4" SD_2="4.1" SE="3.167574689216453" STUDY_ID="STD-Vanhole-1997" TOTAL_1="17" TOTAL_2="17" WEIGHT="48.51284854637097"/>
<CONT_DATA CI_END="8.52634388649482" CI_START="-3.5263438864948196" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="106.5" MEAN_2="104.0" ORDER="88605" SD_1="18.5" SD_2="19.9" SE="3.074721746945276" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="82" TOTAL_2="75" WEIGHT="51.48715145362903"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.198651971777403" CI_END="5.239302131010049" CI_START="-4.8039466463087255" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.21767774235066203" ESTIMABLE="YES" I2="76.18283185360866" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="0.04045626488862719" P_Q="1.0" P_Z="0.9322926643134881" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="92" UNITS="" WEIGHT="100.0" Z="0.08496066257101842">
<NAME>Bayley PDI at 7-12 months in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.0798886633544926" CI_START="-12.079888663354492" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="88.0" MEAN_2="93.0" ORDER="1" SD_1="12.4" SD_2="8.25" SE="3.612254469571763" STUDY_ID="STD-Vanhole-1997" TOTAL_1="17" TOTAL_2="17" WEIGHT="50.30783102523179"/>
<CONT_DATA CI_END="12.623611858955789" CI_START="-1.6236118589557886" EFFECT_SIZE="5.5" ESTIMABLE="YES" MEAN_1="98.3" MEAN_2="92.8" ORDER="88607" SD_1="22.8" SD_2="22.7" SE="3.634562632347293" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="82" TOTAL_2="75" WEIGHT="49.692168974768215"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.208062794298819" CI_START="-11.208062794298819" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.3734869298140999" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="75" UNITS="" WEIGHT="99.99999999999999" Z="0.8899608278962151">
<NAME>Bayley MDI at 24 months in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.208062794298819" CI_START="-11.208062794298819" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="93.2" MEAN_2="96.7" ORDER="88608" SD_1="22.5" SD_2="26.4" SE="3.9327573644715077" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="82" TOTAL_2="75" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.509856743884855" CI_START="-3.3098567438848665" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.0999999999999943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.34318155649402815" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="75" UNITS="" WEIGHT="99.99999999999999" Z="0.9478976824046315">
<NAME>Bayley PDI at 24 months in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.509856743884855" CI_START="-3.3098567438848665" EFFECT_SIZE="3.0999999999999943" ESTIMABLE="YES" MEAN_1="89.3" MEAN_2="86.2" ORDER="88609" SD_1="20.1" SD_2="20.8" SE="3.270395167689301" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="82" TOTAL_2="75" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.7104916559028327" CI_START="-7.91049165590285" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.1000000000000085" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.47872125026583867" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="75" UNITS="" WEIGHT="100.0" Z="0.7083607741442653">
<NAME>RAKIT IQ score at 5 years in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.7104916559028327" CI_START="-7.91049165590285" EFFECT_SIZE="-2.1000000000000085" ESTIMABLE="YES" MEAN_1="93.6" MEAN_2="95.7" ORDER="88610" SD_1="16.2" SD_2="20.4" SE="2.964591034190045" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="81" TOTAL_2="75" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.3093710542579087" CI_END="1.2497419182102847" CI_START="0.37197762696764247" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6818181818181818" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.0968203369525126" LOG_CI_START="-0.4294831804855626" LOG_EFFECT_SIZE="-0.16633142176652504" METHOD="MH" NO="8" P_CHI2="0.5780664943869858" P_Q="0.0" P_Z="0.21540383595276447" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="120" TOTAL_2="120" WEIGHT="100.00000000000001" Z="1.2388425513347943">
<NAME>Neonatal mortality</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.372816405310655" CI_START="0.22868556722059719" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6407612436759104" LOG_CI_START="-0.6407612436759105" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.7527726527090809" STUDY_ID="STD-Vanhole-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.5666666666666665" WEIGHT="13.636363636363637"/>
<DICH_DATA CI_END="1.2310979128206556" CI_START="0.3240131939181613" EFFECT_SIZE="0.631578947368421" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.09029259501635631" LOG_CI_START="-0.4894373048267646" LOG_EFFECT_SIZE="-0.19957235490520417" ORDER="88612" O_E="0.0" SE="0.3405362128771355" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="100" TOTAL_2="100" VAR="0.11596491228070173" WEIGHT="86.36363636363637"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3669295192188945" CI_END="1.257229261818848" CI_START="0.4247623602607491" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7307692307692307" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.09941448060084289" LOG_CI_START="-0.37185397463682096" LOG_EFFECT_SIZE="-0.13621974701798903" METHOD="MH" NO="9" P_CHI2="0.8323812539289538" P_Q="0.0" P_Z="0.2571924975668045" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="142" WEIGHT="100.0" Z="1.1330518525954523">
<NAME>Mortality to discharge</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.480206230341023" CI_START="0.15431607644181022" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8115888273634806" LOG_CI_START="-0.8115888273634805" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.9534625892455924" STUDY_ID="STD-Amato-1989" TOTAL_1="22" TOTAL_2="22" VAR="0.9090909090909092" WEIGHT="7.6923076923076925"/>
<DICH_DATA CI_END="1.2353711589146819" CI_START="0.35976592236045474" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.09179745804229697" LOG_CI_START="-0.4439799761536595" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="2" O_E="0.0" SE="0.31471831698777725" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="100" TOTAL_2="100" VAR="0.09904761904761905" WEIGHT="80.76923076923077"/>
<DICH_DATA CI_END="4.372816405310655" CI_START="0.22868556722059719" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6407612436759104" LOG_CI_START="-0.6407612436759105" LOG_EFFECT_SIZE="0.0" ORDER="4" O_E="0.0" SE="0.7527726527090809" STUDY_ID="STD-Vanhole-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.5666666666666665" WEIGHT="11.538461538461538"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1356571496403007" CI_START="0.431468247397728" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.05524723939178414" LOG_CI_START="-0.3650511593632706" LOG_EFFECT_SIZE="-0.1549019599857432" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.14854255186254986" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="1.4446986408038034">
<NAME>Death or cerebral palsy</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1356571496403007" CI_START="0.431468247397728" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="0.05524723939178414" LOG_CI_START="-0.3650511593632706" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="1" O_E="0.0" SE="0.24688535993934704" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="100" TOTAL_2="100" VAR="0.060952380952380945" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9673888954995804" CI_START="0.1895605934406179" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.47237446714650794" LOG_CI_START="-0.7222519403631077" LOG_EFFECT_SIZE="-0.12493873660829993" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.6818341823470917" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="0.40996151179461165">
<NAME>Air leak</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9673888954995804" CI_START="0.1895605934406179" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.47237446714650794" LOG_CI_START="-0.7222519403631077" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="1" O_E="0.0" SE="0.701729465267237" STUDY_ID="STD-Amato-1989" TOTAL_1="22" TOTAL_2="22" VAR="0.4924242424242424" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.1309268055407134" CI_END="0.7178336439043047" CI_START="-5.2729021289783535" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.2775342425370244" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.12" NO="12" P_CHI2="0.7174731091876463" P_Q="1.0" P_Z="0.13615517110955522" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="39" UNITS="" WEIGHT="100.0" Z="1.4902627183576558">
<NAME>Duration of mechanical ventilation (days)</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0459489532134318" CI_START="-5.245948953213431" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="14.6" ORDER="1" SD_1="5.8" SD_2="4.8" SE="1.605105490727521" STUDY_ID="STD-Amato-1989" TOTAL_1="22" TOTAL_2="22" WEIGHT="90.65609249805134"/>
<CONT_DATA CI_END="5.799093556186714" CI_START="-13.799093556186714" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="14.0" ORDER="2" SD_1="12.37" SD_2="16.49" SE="4.999629398030123" STUDY_ID="STD-Vanhole-1997" TOTAL_1="17" TOTAL_2="17" WEIGHT="9.343907501948669"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.49665991688438615" CI_END="1.282285449043798" CI_START="0.7231663763563547" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9629671446313651" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.10798471406362843" LOG_CI_START="-0.14076177459901593" LOG_EFFECT_SIZE="-0.016388530267693782" METHOD="MH" NO="13" P_CHI2="0.780102508703907" P_Q="0.0" P_Z="0.7962044245071023" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="118" WEIGHT="100.0" Z="0.2582623719186446">
<NAME>CLD in survivors (oxygen at 28 days)</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0086608078120443" CI_START="0.2212640594748102" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3029066058709399" LOG_CI_START="-0.6550891239823023" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="2" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Amato-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="11.448571751157276"/>
<DICH_DATA CI_END="1.642958312138172" CI_START="0.6086581702116253" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.2156265439353387" LOG_CI_START="-0.2156265439353387" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.25332019855244947" STUDY_ID="STD-Vanhole-1997" TOTAL_1="17" TOTAL_2="17" VAR="0.06417112299465241" WEIGHT="20.989048210455007"/>
<DICH_DATA CI_END="1.4279680518090982" CI_START="0.7026382959830414" EFFECT_SIZE="1.0016711229946524" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="34" LOG_CI_END="0.1547184909988199" LOG_CI_START="-0.15326818349237786" LOG_EFFECT_SIZE="7.251537532210107E-4" ORDER="88622" O_E="0.0" SE="0.18091289715475606" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="88" TOTAL_2="81" VAR="0.03272947635692734" WEIGHT="67.56238003838772"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0637236102516432" CI_END="1.7439855534157456" CI_START="0.6459786356755453" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0614035087719298" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" I2="5.990617265378571" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.24154288306340038" LOG_CI_START="-0.18978184510344545" LOG_EFFECT_SIZE="0.025880518979977476" METHOD="MH" NO="14" P_CHI2="0.30236784154961593" P_Q="0.0" P_Z="0.8140495580995626" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="98" WEIGHT="99.99999999999999" Z="0.23520508697725143">
<NAME>CLD in survivors (oxygen at 36 weeks)</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6601956347279412" CI_START="0.49891981985751127" EFFECT_SIZE="0.9101123595505618" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.2201592676043092" LOG_CI_START="-0.30196924313683526" LOG_EFFECT_SIZE="-0.040904987766263036" ORDER="2" O_E="0.0" SE="0.30670087178716" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="89" TOTAL_2="81" VAR="0.09406542475500396" WEIGHT="78.07017543859648"/>
<DICH_DATA CI_END="3.9059197408280344" CI_START="0.6554154129796055" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5917233151234644" LOG_CI_START="-0.18348334981161493" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="3" O_E="0.0" SE="0.45536023231774486" STUDY_ID="STD-Vanhole-1997" TOTAL_1="17" TOTAL_2="17" VAR="0.20735294117647057" WEIGHT="21.929824561403507"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8838215820692678" CI_END="1.1900569838236474" CI_START="0.5567130736079751" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.813953488372093" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.0755677573317379" LOG_CI_START="-0.25436857979035965" LOG_EFFECT_SIZE="-0.08940041122931089" METHOD="MH" NO="15" P_CHI2="0.6428070014206437" P_Q="0.0" P_Z="0.28816583278884644" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="142" WEIGHT="100.0" Z="1.0621539157578535">
<NAME>Patent ductus arteriosus</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6064627627310486" CI_START="0.5011091919882401" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4160515247527956" LOG_CI_START="-0.3000676307974221" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="2" O_E="0.0" SE="0.42065193681718843" STUDY_ID="STD-Amato-1989" TOTAL_1="22" TOTAL_2="22" VAR="0.1769480519480519" WEIGHT="16.27906976744186"/>
<DICH_DATA CI_END="1.1801649524439484" CI_START="0.444324110860093" EFFECT_SIZE="0.7241379310344828" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="29" LOG_CI_END="0.07194271317859051" LOG_CI_START="-0.3523001195086642" LOG_EFFECT_SIZE="-0.1401787031650368" ORDER="3" O_E="0.0" SE="0.2492023399563842" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="100" TOTAL_2="100" VAR="0.062101806239737274" WEIGHT="67.44186046511628"/>
<DICH_DATA CI_END="2.102230118933325" CI_START="0.3494830898549799" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.32268025399138267" LOG_CI_START="-0.45657383325260914" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="4" O_E="0.0" SE="0.4577377082170635" STUDY_ID="STD-Vanhole-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.20952380952380956" WEIGHT="16.27906976744186"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1709114155478381" CI_END="1.6290525154092146" CI_START="0.877555577527762" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1956521739130435" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.21193508479028852" LOG_CI_START="-0.056725369164949" LOG_EFFECT_SIZE="0.07760485781266976" METHOD="MH" NO="16" P_CHI2="0.9180938419415064" P_Q="0.0" P_Z="0.2575064393172718" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="142" WEIGHT="99.99999999999999" Z="1.1323045435151908">
<NAME>Intraventricular hemorrhage - any grade</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.275358036443697" CI_START="0.3369966105610984" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7222519403631077" LOG_CI_START="-0.4723744671465079" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="1" O_E="0.0" SE="0.701729465267237" STUDY_ID="STD-Amato-1989" TOTAL_1="22" TOTAL_2="22" VAR="0.4924242424242424" WEIGHT="6.521739130434782"/>
<DICH_DATA CI_END="1.7005397330106575" CI_START="0.8698308283385577" EFFECT_SIZE="1.2162162162162162" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="37" LOG_CI_END="0.23058678365226676" LOG_CI_START="-0.060565204235569395" LOG_EFFECT_SIZE="0.08501078970834869" ORDER="2" O_E="0.0" SE="0.1710241189108988" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="100" TOTAL_2="100" VAR="0.02924924924924925" WEIGHT="80.43478260869564"/>
<DICH_DATA CI_END="2.577326316861588" CI_START="0.38799898695703405" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4111694083221442" LOG_CI_START="-0.4111694083221443" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.48304589153964794" STUDY_ID="STD-Vanhole-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.23333333333333334" WEIGHT="13.043478260869565"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2367369887796447" CI_END="2.415407541310685" CI_START="0.5635119903503012" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="0.3829904179073694" LOG_CI_START="-0.2490968386461429" LOG_EFFECT_SIZE="0.06694678963061322" METHOD="MH" NO="17" P_CHI2="0.6265728558611655" P_Q="0.0" P_Z="0.6780140703300672" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="120" TOTAL_2="120" WEIGHT="100.0" Z="0.41517463038893904">
<NAME>Intraventricular hemorrhage - grade 3 or 4</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3555210007077925" CI_START="0.5052311757231204" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.37208698055508593" LOG_CI_START="-0.29650985877628644" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="1" O_E="0.0" SE="0.3927370930309795" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="100" TOTAL_2="100" VAR="0.15424242424242424" WEIGHT="91.66666666666667"/>
<DICH_DATA CI_END="20.332240770599807" CI_START="0.19673188238966538" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3081852438953019" LOG_CI_START="-0.7061252525673394" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="2" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-Vanhole-1997" TOTAL_1="20" TOTAL_2="20" VAR="1.4" WEIGHT="8.333333333333334"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.705078767310894" CI_START="0.18428866547235168" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="1.3365613662238505" LOG_CI_START="-0.7345013748958881" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" NO="18" P_CHI2="1.0" P_Q="0.0" P_Z="0.568838135954588" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="0.5697634726880932">
<NAME>Periventricular leukomalacia</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.705078767310894" CI_START="0.18428866547235168" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3365613662238505" LOG_CI_START="-0.7345013748958881" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1" O_E="0.0" SE="1.2165525060596438" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="100" TOTAL_2="100" VAR="1.48" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.763080139825827" CI_START="0.014312761057443371" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.19" LOG_CI_END="0.8900340694951818" LOG_CI_START="-1.8442765789345066" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="19" P_CHI2="1.0" P_Q="0.0" P_Z="0.49397229117736974" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="0.6840045596473466">
<NAME>Necrotizing enterocolitis</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.763080139825827" CI_START="0.014312761057443371" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8900340694951818" LOG_CI_START="-1.8442765789345066" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="2" O_E="0.0" SE="1.6061476099435992" STUDY_ID="STD-Amato-1989" TOTAL_1="22" TOTAL_2="22" VAR="2.5797101449275357" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0016479520337266955" CI_END="2.0085737801961527" CI_START="0.49151138915068254" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9935979513444302" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="0.30288778913891556" LOG_CI_START="-0.30846641437713934" LOG_EFFECT_SIZE="-0.002789312619111903" METHOD="MH" NO="20" P_CHI2="0.9676187957083294" P_Q="0.0" P_Z="0.985730811170314" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="101" WEIGHT="100.0" Z="0.017884729486247336">
<NAME>Retinopathy of prematurity (any grade) in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0401873360943665" CI_START="0.49015106716344514" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.3096700474732594" LOG_CI_START="-0.3096700474732594" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.3638034375544994" STUDY_ID="STD-Vanhole-1997" TOTAL_1="17" TOTAL_2="17" VAR="0.13235294117647056" WEIGHT="88.60435339308579"/>
<DICH_DATA CI_END="14.84860645757795" CI_START="0.05999193386489131" EFFECT_SIZE="0.9438202247191011" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.171685697007932" LOG_CI_START="-1.221907138173994" LOG_EFFECT_SIZE="-0.025110720583031137" ORDER="88636" O_E="0.0" SE="1.4060082798614872" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="89" TOTAL_2="84" VAR="1.9768592830390583" WEIGHT="11.395646606914212"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.470855531429504" CI_END="1.5655594044751218" CI_START="0.6734515025429455" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.026804914900591" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-002.21" LOG_CI_END="0.1946695513820448" LOG_CI_START="-0.17169367378857575" LOG_EFFECT_SIZE="0.011487938796734536" METHOD="MH" NO="21" P_CHI2="0.7902327493198378" P_Q="0.0" P_Z="0.9021736362828676" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="227" TOTAL_2="208" WEIGHT="300.0" Z="0.12291597382741733">
<NAME>Clinically significant behavioural problems in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormones</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0510002531131397E-31" CI_END="1.8634384992398578" CI_START="0.34798505758420367" DF="0.0" EFFECT_SIZE="0.8052631578947369" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="100.0" ID="CMP-002.21.01" LOG_CI_END="0.27031506390954413" LOG_CI_START="-0.45843940418000434" LOG_EFFECT_SIZE="-0.09406217013523012" NO="1" P_CHI2="0.0" P_Z="0.6128882764110803" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="68" WEIGHT="100.00000000000001" Z="0.5059549514832653">
<NAME>Clinically significant CBCL score at 2 years</NAME>
<DICH_DATA CI_END="1.8634384992398574" CI_START="0.3479850575842036" EFFECT_SIZE="0.8052631578947368" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.270315063909544" LOG_CI_START="-0.4584394041800044" LOG_EFFECT_SIZE="-0.09406217013523017" ORDER="88637" O_E="0.0" SE="0.4280739819485971" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="76" TOTAL_2="68" VAR="0.1832473340213278" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.402748537090048" CI_START="0.5706082338662024" DF="0.0" EFFECT_SIZE="1.170909090909091" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" ID="CMP-002.21.02" LOG_CI_END="0.38070832150356637" LOG_CI_START="-0.24366196577242985" LOG_EFFECT_SIZE="0.06852317786556826" NO="2" P_CHI2="1.0" P_Z="0.6670480384931041" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="69" WEIGHT="100.0" Z="0.4302029211181178">
<NAME>Clinically significant CBCL score at 5 years</NAME>
<DICH_DATA CI_END="2.402748537090048" CI_START="0.5706082338662024" EFFECT_SIZE="1.170909090909091" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.38070832150356637" LOG_CI_START="-0.24366196577242985" LOG_EFFECT_SIZE="0.06852317786556826" ORDER="88638" O_E="0.0" SE="0.36675819742868815" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="75" TOTAL_2="69" VAR="0.13451157538114059" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1034644598482335" CI_START="0.5523955200844749" DF="0.0" EFFECT_SIZE="1.0779352226720649" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" I2="0.0" ID="CMP-002.21.03" LOG_CI_END="0.32293517857208265" LOG_CI_START="-0.2577498521978258" LOG_EFFECT_SIZE="0.032592663187128446" NO="3" P_CHI2="1.0" P_Z="0.8258574945647601" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="71" WEIGHT="100.0" Z="0.2200175400503076">
<NAME>Clinically significant TRF score at 5 years</NAME>
<DICH_DATA CI_END="2.1034644598482335" CI_START="0.5523955200844748" EFFECT_SIZE="1.0779352226720649" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.32293517857208265" LOG_CI_START="-0.25774985219782587" LOG_EFFECT_SIZE="0.032592663187128446" ORDER="88639" O_E="0.0" SE="0.34109726151150493" STUDY_ID="STD-van-Wassenaer-1997" TOTAL_1="76" TOTAL_2="71" VAR="0.11634734181064797" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Thyroid hormones as treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Neonatal mortality</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.414774237929704" CI_START="0.077204026880898" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="1.187937168508564" LOG_CI_START="-1.1123600467297645" LOG_EFFECT_SIZE="0.037788560889399754" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.9486554351147425" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="0.06439534672318313">
<NAME>Mortality to discharge</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.414774237929704" CI_START="0.077204026880898" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.187937168508564" LOG_CI_START="-1.1123600467297645" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="1" O_E="0.0" SE="1.3512059708858513" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" VAR="1.825757575757576" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9227329034845608" CI_START="0.45474149384109297" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.935064935064935" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.28391895839376385" LOG_CI_START="-0.3422354158761907" LOG_EFFECT_SIZE="-0.029158228741213422" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.8551590453533728" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="0.18253989921380073">
<NAME>CLD in survivors (oxygen at 28 days)</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9227329034845608" CI_START="0.45474149384109297" EFFECT_SIZE="0.935064935064935" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.28391895839376385" LOG_CI_START="-0.3422354158761907" LOG_EFFECT_SIZE="-0.029158228741213422" ORDER="1" O_E="0.0" SE="0.3678061789603123" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" VAR="0.13528138528138528" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.5705924916828753" CI_START="0.1481338520334534" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.552740287405811" LOG_CI_START="-0.829345683738374" LOG_EFFECT_SIZE="-0.13830269816628143" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.694866345352144" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="0.3922596901062769">
<NAME>CLD in survivors (oxygen at 36 weeks)</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5705924916828753" CI_START="0.14813385203345344" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.552740287405811" LOG_CI_START="-0.8293456837383739" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="1" O_E="0.0" SE="0.8118441408859887" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" VAR="0.659090909090909" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5586207671985255" CI_START="0.24932197924637545" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6233766233766234" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.1927404585191259" LOG_CI_START="-0.6032394341129153" LOG_EFFECT_SIZE="-0.20524948779689467" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.31212015635193435" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="1.0107833317170747">
<NAME>Patent ductus arteriosus</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5586207671985255" CI_START="0.2493219792463754" EFFECT_SIZE="0.6233766233766234" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.1927404585191259" LOG_CI_START="-0.6032394341129154" LOG_EFFECT_SIZE="-0.20524948779689467" ORDER="1" O_E="0.0" SE="0.4675625290960757" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" VAR="0.21861471861471865" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.039573882065785" CI_START="0.016219918677380755" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.36111111111111116" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.905233030642515" LOG_CI_START="-1.7899513275634158" LOG_EFFECT_SIZE="-0.44235914846045044" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.5199803810336917" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="0.6433756537466847">
<NAME>Necrotising enterocolitis</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.039573882065785" CI_START="0.016219918677380755" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.905233030642515" LOG_CI_START="-1.7899513275634158" LOG_EFFECT_SIZE="-0.4423591484604505" ORDER="1" O_E="0.0" SE="1.583164633387904" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" VAR="2.506410256410256" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.5705924916828753" CI_START="0.1481338520334534" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.552740287405811" LOG_CI_START="-0.829345683738374" LOG_EFFECT_SIZE="-0.13830269816628143" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.694866345352144" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="0.3922596901062769">
<NAME>Retinopathy of prematurity (any grade) in survivors</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5705924916828753" CI_START="0.14813385203345344" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.552740287405811" LOG_CI_START="-0.8293456837383739" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="1" O_E="0.0" SE="0.8118441408859887" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" VAR="0.659090909090909" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.5658529365102396" CI_START="-2.5458529365102436" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.509999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.743589248553566" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.3271039715860599">
<NAME>Weight gain (grams/day)</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.5658529365102396" CI_START="-2.5458529365102436" EFFECT_SIZE="0.509999999999998" ESTIMABLE="YES" MEAN_1="16.08" MEAN_2="15.57" ORDER="1" SD_1="4.3" SD_2="3.0" SE="1.5591372905902452" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.1875896844445128" CI_START="-0.14758968444451276" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.81506237020121" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.23390031326050736">
<NAME>Growth head circumference (cm/week)</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1875896844445128" CI_START="-0.14758968444451276" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="0.78" MEAN_2="0.76" ORDER="1" SD_1="0.2" SD_2="0.21" SE="0.08550651224534676" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.1212705819964073" CI_START="-0.2412705819964072" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.05999999999999994" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.10" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.516505159110914" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.6487419954040525">
<NAME>Growth length (cm/week)</NAME>
<GROUP_LABEL_1>Thyroid hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1212705819964073" CI_START="-0.2412705819964072" EFFECT_SIZE="-0.05999999999999994" ESTIMABLE="YES" MEAN_1="0.67" MEAN_2="0.73" ORDER="1" SD_1="0.26" SD_2="0.17" SE="0.09248669027913087" STUDY_ID="STD-Chowdhry-1984" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>